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Cancer is a leading cause of death globally, and it was responsible for 8.8 million deaths in 
2015. It is predicted that there will be 22 million new cancer cases by 2030 worldwide. 
Approximately, 70% of deaths from cancer occur in low- and middle-income countries. 
Furthermore, breast cancer is the second most common cancer among South African women 
and is reported to affect 1 in every 26 women. The social and economic burdens associated 
with cancers are severe at national and international levels hence, there is an urgent need for 
the development of more effective cancer therapeutics. To accomplish this aspect, in this 
study, thiadiazole-thiazolone (TDT) hybrids were developed as dual inhibitors of cyclin-
dependent kinase (CDK) and kinesin spindle protein (KSP), respectively. Twenty-two novel 
TDT hybrid compounds (8a-v) were synthesized using multistep organic synthesis and were 
characterized using thin layer chromatography (TLC), infrared spectroscopy (FT-IR), nuclear 
magnetic resonance spectroscopy (1H and 13C NMR), and high-resolution mass spectrometry 
(HR-MS). All the compounds (8a-v) were screened for their potential in vitro inhibition of 
validated anticancer drug targets (CDK, Abl and KSP) and cancer cell lines (MCF-7 and K-
562). Results obtained from these evaluations suggested that the synthesized compounds 
were potent inhibitors of CDK and KSP thus confirming the dual mode of action. Amongst, 
8h was identified as the most potent compound with an IC50 value of 3.1 µM against CDK2 
enzyme and exhibited good cytotoxicity (GI50 = 6.25 µM) against the tested cancer cell lines 
(MCF-7 and K-562). A brief structure-activity relationship (SAR) analysis indicated that 2-
chloro and 4-nitro substituents on the phenyl ring of the thiazolone motif contributed 
significantly to the inhibition of both of the anticancer drug targets (CDK and KSP). An in 
silico molecular docking study using the crystal structures of the target enzymes (CDK-2 and 
KSP) further supported the SAR and extrapolated the importance of crucial molecular 
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1.1.  Background and rationale of this study 
Cancer, also known as a malignant neoplasm, is a disease that involves abnormal growth of 
cells with the ability to invade or spread to other parts of the body [1]. There are more than 
100 known cancers that can affect different parts of the body. There have been 14.1 million 
new cancer cases, 8.8 million cancer deaths and 32.6 million people living with cancer that 
were reported by World Health Organization (WHO 2015) worldwide. The treatment is 
estimated to cost world economies as much as US$1.16 trillion annually. African countries 
(including South Africa) have a high risk of dying from cancer than USA and UK. The 
disease is most common in developing countries (South Africa, sub-Saharan Africa, and 
Asia) where resources for constant diagnosis and treatment access are limited [2]. Moreover, 
there is a lot of social and economic burden associated with this dangerous disease nationally 
and internationally [3]. The current chemotherapy is unable to combat cancer effectively due 
to multiple factors such as mutation of genes, genetic variation, altered lifestyle and inability 
to target specific proteins. Though there have been developments in the prevention and 
treatment of cancer, a successful cancer therapy remains a challenge till date [4]. In general, 
chemotherapy involves the administration of chemical-based drugs to arrest the growth/kill 
cancer cells. However, due to these drugs being non-specific, it also destroys the host cells. 
Furthermore, drug resistance and mutations are a persistent problem during the treatment of 
cancer with chemotherapeutic drugs [5]. Thus, there is an urgent need to develop new, safe 
and efficacious anti-cancer agents possessing a broad spectrum of cytotoxicity to tumour cells 
and which are free of host cell toxicity [6].  
Cyclin-dependent kinases (CDKs) and mitotic motor proteins are well-validated 
checkpoint proteins and the researchers worldwide have focused in developing newer 
inhibitors of these target enzymes as potential anticancer agents. Hence, the proposed work 
aims to develop dual inhibitors exhibiting potential and effective anticancer agents with a 
novel mechanism of action. CDKs are universal eukaryotic cell cycle regulators that promote 
the passage through the restriction point, mitosis, and initiation of deoxyribonucleic acid 
(DNA) replication [7]. Given the fact that CDKs have oncogenic potency and are amenable 
to pharmacological inhibition, their inhibitors have therefore attracted great interest as 
potential anticancer agents specifically, CDK2 [8]. The CDK enzyme plays an important role 
in regulating various events of eukaryotic cell division cycle. Accumulated evidence 
indicated that overexpression of CDK2 causes the abnormal regulation of cell cycle, which is 
directly associated with hyperproliferation in cancer cells. Therefore, CDK2 is also regarded 
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as a potential therapeutic target for cancer therapy [9]. Another interesting mitotic target is 
kinesin spindle protein (KSP; also, known as Eg5), a member of the kinesin superfamily of 
molecular motor proteins [10]. Inhibition of KSP prevents spindle pole separation, which 
leads to a prolonged mitotic arrest in prometaphase and subsequent apoptosis [11]. 
Furthermore, KSP is not expressed in the adult peripheral nervous system and its inhibitors 
may not cause neuropathic side effects. As evidenced by literature, inhibitors of KSP arrest 
only cells in mitosis and are not expected to affect non-proliferating cells [12]. Currently, 
there are many KSP inhibitors under phase-I or II stages of clinical trials [13]. Interestingly, 
many of the available KSP inhibitors are not adenosine triphosphate (ATP)-competitive 
inhibitors they are rather allosteric inhibitors. Hence, this research also aimed to consider the 
enzymes that target KSP to minimize the side effects of cancer chemotherapy. 
1.2.  Aims of this study  
1.2.1.  Identification of small organic molecules as potent anticancer agents; 
1.2.2.  To employ rational drug design approaches through suitable computational    
 techniques (in silico); 
1.2.3.  Design target site-specific inhibitors on the binding-site of CDK and KSP; 
1.2.4.  Organic syntheses of designed molecules by conventional and/or microwave-   
 assisted organic green chemistry approaches; 
1.2.5.  Pharmacological evaluation of the final compounds against CDK and KSP  
 using suitable in vitro methods; and 
1.2.6.  Cytotoxicity assays using cancer cell lines (MCF and K-562).  
 
1.3.  Objectives of this study  
1.3.1.  Design of potential anticancer compounds through molecular hybridization  
             approach; 
1.3.2.  Synthesis of the designed molecules using green chemistry approaches; 
1.3.3.  Characterization of the synthesized compounds by suitable chromatographic,   
 spectral methods or by single crystal X-ray crystallography; 
1.3.4.  Pharmacological evaluation for the newly synthesized final compounds by   
 suitable in vitro methods (enzyme assays); 
1.3.5.  Cytotoxicity studies for the synthesized final compounds against cancer cell  
 lines; and 
1.3.6.  To develop crystal structures of the potent final compounds. 
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1.4.  Novelty and significance of this study  
The main aspect of this study is to develop novel anticancer drug-like compounds for cancer 
chemotherapy with no neuropathic side effects. The research work presented in this thesis 
involves the design and synthesis of novel thiadiazole-thiazolone (TDT) hybrid compounds 
as dual inhibitors for CDK and KSP. As per the literature survey, there is no research report 
so far on TDT compounds as dual inhibitors of CDK and KSP. This work is the first of its 
kind and all the findings on these novel derivatives are reported in this thesis. Hence, the 
entire research work is novel and could serve as an ideal alternative path for medicinal and 
pharmaceutical chemists. The outcome of this research work resulted in one published 
research paper and two other research articles that are under communications/preparation for 
high impact journals. 
1.5.  Outline and structure of this thesis  
This thesis is divided into seven different chapters. 
Chapter 1: This chapter addresses the overview, aims, objectives, significance of the study,   
                    general outline and structure of the thesis; 
Chapter 2: This introductory chapter gives a detailed literature survey, background and the  
                    design of the present study;  
Chapter 3: This chapter describes the synthesis and spectral studies including experimental 
                    section); 
Chapter 4: This chapter addresses the in vitro and in silico evaluation of the synthesized  
                    compounds against cyclin dependent kinase and cancer cell-lines; 
Chapter 5: This chapter describes the in vitro and in silico evaluation of the compounds   
                    against kinesin spindle protein;  
Chapter 6: This chapter gives a summary and conclusion of the study as well as future  
                    perspectives of the work; and 
Chapter 7: Gives all the necessary supporting documents pertaining the spectral studies and  
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2.1.  Cancer  
2.1.1. The overview  
Cancer is a disease also known as malignant neoplasm or tumour. The uncontrollable division 
of cells causes this disease. There are two types of cancer including the one classified as 
malignant that can invade and spread to different body parts [1]. Some tumours are classified 
as benign, meaning they are localized and do not spread to other body organs [2]. Cancer 
cells behave differently from normal cells in that, the latter undergo controlled mitotic or 
meiotic cell divisions creating new daughter cells based on what is needed by the body. The 
normal cell growth is intended to replace old or damaged cells. However, in cancer cells, this 
growth gets more and more abnormal and uncontrollable, leading to old, and damaged cells 
dying and new cells being excessively formed when they not required. Other cancerous cells 
detach themselves from the tumour and migrate via the circulatory system(s) to different 
body parts [3]. Cancer cells can “hide” from the immune system, tissues, organs, and other 
specialized cells essential for homeostasis. Although there have been considerable 
developments in the prevention and treatment of cancer, successful chemotherapy for 
numerous types of cancer remains a greater challenge till date [2]. Therefore, it is very 
imperative to establish new, safe and efficacious chemotherapeutic agents exhibiting a broad 
spectrum of anticancer properties with devoid of host cell toxicity [4].  
2.1.2. Cancer prevalence  
Cancer is a leading cause of death globally, and it was responsible for 8.8 million deaths in 
2015 [5]. Many cancer deaths are due to liver, lung, colorectal, breast, and stomach cancers. 
Over 60% of world’s total new incidences take place in Africa, Asia, Central and South 
America [6]. These regions account for 70% of the world’s cancer deaths. Predictions suggest 
that by 2030, 23.6 million new cancer cases would arise worldwide if current drifts in the 
occurrence of major cancers and population development are seen universally in the future 
[7]. This is 68% more scenarios compared to 2012, with somewhat larger development in low 
and medium human development index (HDI) countries (66% raise in 2030 compared to 
2012) than in high and extremely high HDI countries (56% raise in 2030 compared to 2012). 
Cancer tends to affect young people and reduces the work efficiency and quality of life, 
which has caused an immense damage to the national and the international economy. Thus, 
the human, social and economic burdens associated with several cancers are severe [8]. 
Therefore, there is an urgent need for the development of more effective cancer therapeutics 
and strategies at this point in time. 
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2.1.3.  The hallmarks of cancer  
Cancer is a type of disease that is extremely miscellaneous and complex. There are six 
recognized traits that jointly result to cancer disease (Fig. 1). Such traits develop in diverse 
orders and are said to offer the basis for tumourigenesis [9]. The capacity of cancer cells to 
develop independency or insusceptibility toward normal growth signals responsible for 
control of usual tissue propagation is due to the independence of the signals for development 
and anti-growth insusceptibility. Apoptosis is defined as programmed cell death (PCD) which 
is a genetically encoded process that leads to cell death [10]. During tumour development 
apoptosis causes a critical attrition to the population of the cell and the ability to escape PCD 
forms an additional carcinogenesis phase. These capabilities, for example, deregulation of 
custom mechanisms of cell development is insufficient for cancer growth since ordinary cells 
are restricted in terms of replication [11]. Malignant cells divide without stopping, this occurs 
via the maintenance of telomeres and evasion of senescence, thus enabling continuous 
expansion. Cancer cells should be nourished to increase their growth as well as to achieve 
their capacity to trigger and maintain the angiogenesis [12]. The source of death in 90% of 
cancer patients is because of the invasion of the nearby tissues, and the capacity to spread to 
other organs which is characteristically the ultimate alteration in the cancer evolution [13]. 
 
Figure 1: The proposed six assimilated biological abilities gained throughout the entire  
     tumour development [9].  
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2.1.4. Different types of cancer  
Cancer exists in different forms and they are named based on the organs they invaded. The 
most common type of cancer is the carcinoma, which is formed by the epithelial cells [14]. 
Another form of cancer is the sarcoma which occurs in the bone and soft tissues, like 
muscles, fats, and blood vessels. There exist numerous forms of the spinal cord as well as 
brain tumours, named based on the cell type they develop on [15]. For instance, the astrocytic 
tumour initiates on the star-structured brain cells known as astrocytes, that aid in keeping 
nerve cells physically strong. Brain tumours may be malignant or benign. Another type of 
cancer is leukaemia this cancer activates the blood-forming tissues of the bone marrow. 
These cancer cells are different from others, in that they do not occur in the form of a solid 
tumour, instead abnormal white blood cells develop within the blood as well as bone marrow 
fighting normal blood cells [16]. A decrease in normal blood cells prevents the proper 
transport of oxygen (O2) to different parts of the body, control of bleeding or protection 
against infection. The lymphoma cancer begins in the lymphocytes for example T-cells and B 
cells. These form an important part in the defence and protection of the body against 
infections. This type of cancer forms in the lymph nodes and vessels and on other body parts 
[17]. The multiple myeloma is also known as plasma cell myeloma that forms in the bones 
and spreads throughout the body. Another type of cancer is melanoma which initiates within 
the cells that convert to melanocytes and produce melanin. A lot of melanomas occur on the 
skin; however, they can occur in the pigmented tissues as well, for example, the eye [18]. 
2.1.5. Treatment options 
There are different cancer therapies that have been explored to date. These methods depend 
on the type of cancer found in a patient’s body, and upon how advanced the cancer is in the 
body [19]. These methods include precision medicine, immunotherapy, hormone therapy, 
surgery, stem cell transplant, targeted therapy, and chemotherapy [20]. 
2.1.5.1. Treatment by surgery 
Hypothetically non-haematological cancers are cured after complete removal with surgery, 
however, this is not always doable. When cancerous cells spread to different body parts 
before the surgery, full removal via surgery is normally difficult [21]. Cancer progression by 
the model of Halstedian says that the tumour develops in certain area then invade the lymph 
nodes and finally spreads to the whole body. Small restricted tumours are gradually known as 
potentially metastatic [22]. Illustrations of surgery for cancer comprise mastectomy, 
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prostatectomy, and gastrectomy for breast cancer, prostate cancer and, gastric cancer 
respectively [23]. The purpose of the surgery is to excise an individual tumour or the entire 
organ. An individual cancer cell is microscopic and may redevelop into a new tumour. 
Therefore, pathological studies of the sample from surgery are usually performed to find out 
if an edge of the tissue is healthy or not, hence reducing the possibility that small cancer cells 
hidden from the eye still exist in the patient [24]. In addition to the removal of a tumour, 
surgery is frequently vital in investigating how much the disease has extended as well as 
knowing if it has spread to local lymph nodes [25]. 
2.1.5.2.  Hormonal therapy 
Development of other cancers is normally hindered by producing or inhibiting specific 
hormones secreted in the body. General cases of hormone-sensitive tumours are specific 
types of breast and prostate cancers [26]. Removal or blockage of the hormone testosterone 
or estrogen is usually a significant supplementary treatment. In some cancers, hormone 
agonists administration, for example, progestogens are therapeutically beneficial [27]. 
2.1.5.3.  The immunotherapy 
Immunotherapy of cancer is a treatment tactics that encourages the immune system of the 
patient to attack the tumour [28]. Modern mechanisms of triggering an immune response 
towards tumours include usage of interferons and some cytokines to generate some response 
in the immune of patients with renal cell carcinoma in addition to melanoma as well as 
intravesical Bacillus Calmette-Guérin (BCG) immunotherapy for superficial bladder cancer 
[29]. There has been an intensive exploration of vaccines that can induce specific immune 
responses in several tumours, particularly malignant melanoma. The sipuleucel-T is a therapy 
whereby the patient’s dendritic cells are loaded with prostatic acid phosphatase peptides that 
will trigger certain responses from the immune system to work against prostate-derived cells. 
This vaccine-like approach is applied in the late clinical trials of prostate cancer [30]. The 
allogeneic hematopoietic stem cell transplantation (HSCT) is measured as a form of 
immunotherapy, as the donor's immune cells usually attack the tumour known as a graft-vs-
tumour outcome. Consequently, this HSCT results in a higher treatment percentage compared 
to autologous transplant of numerous types of cancer, though it has severe side effects [31]. 
2.1.5.4.  Photodynamic therapy (PDT) 
This type of therapy involves stimulation of photosensitizing compounds by near-infrared 
(NIR) or visible light [32] regions. After excitation, an extremely energetic phase is created 
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after reacting with O2 yields a highly reactive singlet O2 that is able to induce necrosis and 
PCD within the tumour [33]. The tumour selectivity of porphyrin photosensitizers is due to 
its distinctive leaky vasculature, made up of lymphatic drainage, as well as the high degrees 
of recently generated lipids and collagens. The PDT reduces tumours by directly killing the 
cells, destructing the neo-vasculature tumour, and activating a serious inflammatory response 
that pulls leukocytes to the tumour [34]. 
2.1.5.5.  Photothermal therapy  
The arrival of metal nanoparticles in the 1990's, transformed the photothermal ablation to a 
new area of slightly aggressive tumour treatment [35]. For instance, gold nanoparticles that 
heavily absorb light in the NIR area have been established. This has enabled a deep optical 
penetration into tissues, inducing a dose of heat that is localised and only lethal to the tumour 
cells [36].  
2.1.5.6.  Targeted or biologic drug delivery  
When a drug is transported to a specific location without exposing other body tissues to the 
toxicity, this is known as targeted drug delivery system. This is a vital discrepancy from the 
fundamental targeting concept, where the specific enzyme/receptor is the target and the aim is 
to improve the affinity and binding to the target which eventually initiate the pharmacological 
activity [37]. It involves inhibiting specific fragments within cancer cells, thereby slowing 
down or preventing cancer growth [38]. Other forms of targeted therapies which prevent the 
natural processes that enable successful growth of tumours are discussed in a review by 
Johnsen et al., [39]. For instance, some targeted therapies stop the supply of blood to the 
tumour, leading to the death of cancer cells. In comparison to the traditional chemotherapy, 
targeted agents are precise with reduced side effects that often include infections, weakness, 
and blood count alterations [40]. Drug targeting occurs via physical, biological, or molecular 
mechanisms that lead to increased concentrations of the pharmacologically dynamic agent. 
When it is effectively done, drug targeting can lead to a substantial reduction in the toxicity 
of the drug, a decrease in the drug dose, as well as improved treatment efficiency [42]. In the 
study of cancer, the targeted transport of chemotherapeutics has been shown to significantly 
reduce side effects in comparison to systemic distribution, where tissues in organs such as the 
liver can accumulate toxic levels of drug. Biological agents as well as targeted therapies are 
intended to act on specific cellular targets. For example, there are small molecules that block 
specific protein fragments that are important players in cellular processes that include signal 
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transduction, PCD, cell cycle among other crucial cellular pathways. Diverse forms of 
targeted therapies are schematically illustrated in Fig. 2 [43]. 
 
Figure 2: The diverse forms of targeted therapies [41]. 
2.1.5.7.  Radiation  
This therapy involves the usage of high-energy radiation such as gamma rays, X-rays, and 
charged particles to destroy cancer cells. The radiation is either an external beam radiation 
treatment or internal radiation therapy [44]. Only half of the cancer patients usually receive 
radiation treatment. This radiation therapy destroys cancer cells by damaging their DNA. The 
damage can be done directly or via a charged particle in the cell that can result in DNA 
damage within the cell [45]. However, a disadvantage of radiation therapy is that it is not 
only specific to cancerous cells but also damages the normal cells. To minimize these 
negative side effects of radiation treatment, it is sometimes used in combination with other 
methods such as surgery [46].  
2.2. Cancer chemotherapy  
Cancer chemotherapy is the use of drugs to destroy a tumour. Currently, chemotherapy refers 
to cytotoxic agents with an effect on rapidly dividing cells under ordinary circumstances such 
as bone marrow cells. Chemotherapy has severe side effects [47]. The commonly known side 
effects include; myelosuppression (production of blood cells decreases), mucositis (the 
digestive tract’s lining becomes inflamed) and alopecia (patient loses hair) [48]. 
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Chemotherapy affect not just a specific part of the body but the whole body. 
Chemotherapeutic agents among other ways can be administered orally and intravenously 
(IV). This treatment is either prescribed on its own, or in combination with other cancer 
therapies [2]. In some cases, prior to the surgery or radiation therapy, a type of chemotherapy 
known as neo-adjuvant is used to reduce the size of the tumour. When chemotherapy is used 
to kill cancerous cells that persist after surgery or radiation treatment, it is termed adjuvant 
chemotherapy [49]. Chemotherapy can also aid the efficacy of radiation and biological 
therapies by killing recurrent cancer or metastatic cancer. Chemotherapeutic agents have 
therapeutic guidelines that indicate the dosage levels at which these agents can efficiently 
affect a tumour and levels at which there is unacceptable toxicity. Hence, more efficient 
therapies are a consequence of balancing the beneficial as well as antagonistic properties of a 
combination of different agents, given at different doses throughout the treatment period [32]. 
Cancer treatment via chemotherapy is classified as either curative (to eradicate tumour) or 
palliative (when tumour is thought to be incurable with the aim of keeping a reasonable 
quality of life for as long as possible). Since most anti-cancer agents are extremely toxic, they 
can affect the whole body through a systemic circulation. In most of the cases, they damage 
sensitive tissues in different parts of the body [50]. To restrict this damage, toxicity limits 
should be indicated pertaining the quantity of the drug to be administered at any period [51].  
The main purpose of chemotherapy is to elicit a positive effect of the therapeutic 
objectives without violating the above-stated limitations. There are numerous drugs which are 
suitable as chemotherapeutic agents, and the selection of a particular drug depends on the 
nature of cancer to be treated [47]. These drugs are grouped into five main groups such as 
alkylating drugs, antimetabolites, anthracyclines antibiotics, plant (vinca) alkaloids, and 
topoisomerase inhibitors[52]. Certain drug examples include cisplatin, doxorubicin, 
paclitaxel, 5-fluorouracil, adriamycin, irinotecan, etoposide and chlorambucil. These drugs 
disturb the synthesis and function of DNA or cell division in cancer cells [53]. Based on the 
chosen drug, chemotherapy affects malignant tumours by damaging the DNA/changing the 
composition of DNA of the cancer cells thereby arresting their reproduction/replication [4].  
Chemotherapeutic agents also inhibit the cell’s mitotic processes thus, preventing 
cancerous cells from dividing into new cells. Development of mitotic spindles which are 
important in the movement of the original and replicated DNA to opposite ends of the cell 
(allowing cell division) is also inhibited by some drugs [54]. Clinically, the application of 
traditional anticancer agents renders patients at high risks as most of these drugs are non- 
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specific. This causes many cancer patients to endure major side effects including reduced 
quality of life, and recurring therapy. The inefficiency and side effects of chemotherapy have 
been mainly related to the formulation and bio-distribution of the drug, normal cell toxicity, 
and drug-resistance acquisition by the cancer cells. Therefore, scientists are endlessly 
investigating several ways to overcome these serious problems [50].  
2.3.  Chemotherapeutic agents 
2.3.1. Antimitotic drugs 
Antimitotic agents such as paclitaxel as well as vinblastine activate the spindle assembly 
checkpoint (SAC), this blocks the shift from metaphase to anaphase resulting in 
polymerization inhibition of the microtubule (MT) dynamics [55]. The cells then experience 
mitotic arrest and subsequently, the drug interrupts the growth of spindles and orientation of 
chromosome. This causes the cells to either stay in the prolonged arrest mode resulting in 
initiation of cell death or in the senescence-like G1 mode [56]. Furthermore, MTs develop in 
the interphase and are crucial for accurate segregation of chromosome as well as the division 
of cells in mitosis process. During mitosis, the dynamics of MTs is quicker than during 
interphase, hence, the MTs are validated targets for anticancer drugs because cancer cells 
have a hyperproliferative behaviour [57]. There are two categories namely MT-destabilizing 
agents or MT-stabilizing agents depending on how the agents act on MTs. When the 
destabilizing agents are administered at high concentrations, these agents inhibit the 
polymerization of MTs. Numerous destabilizing agents bind to vinca or taxoid-binding 
domain of mitotic enzymes. In the vinca domain they bind at the vinca site flanked by β- and 
α-tubulin (known as the vinca alkaloids) these consist of vinflunine, vincristine, vinorelbine, 
vindesine, and eribulin [58]. While the ones that bind on the colchicine-site consist of 
cryptophycins, dolastatins, and combretastatin-A4. High dosage of the agents that promote 
MT polymerization stabilizes MTs. They also inhibit calcium ion- or cold-induced 
depolymerization, for example, second- and third-generation taxanes, epothilones and 
ixabepilone. Drugs such as taxanes, attach to the inner surface of the MTs where the taxoid 
binds to the β-tubulin. The peloruside A (PLA) binding arrests the mitotic cell cycle at the 
G2/M state triggering apoptosis. Antimitotic drugs are superior to taxanes as well as vinca 
alkaloids because they are weak substrates of the P-glycoprotein (P-gp) drug efflux pumps 
[57]. 
Antimitotic agents are usually administered in combination with an anthracycline 
(doxorubicin), an antimetabolite (capecitabine), a platinum derivative (carboplatin), or with 
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human epidermal growth factor receptor 2 (HER2) in targeted therapeutics like trastuzumab 
[54]. Regardless of the existence of these effective chemotherapeutic drugs, severe side 
effects (neurotoxicity) and the appearance of mutant tumours, restrict the application of these 
agents, thus raising the need for novel anticancer drugs with reduced side effects [59]. The 
severity of the cancer problem can be judged on the basis that, its morbidity and mortality 
numbers are much greater compared to other diseases [54]. Traditional anticancer drugs (Fig. 
3) have several undesirable side effects including neurotoxicity and drug-resistance that is 
acquired over prolonged chemotherapy [60]. Kinesins are specific to mitosis, play a role in 




Figure 3: Schematic diagram of putative events involved in MT targeting agents (MTA)- 
     induced apoptosis [60]. 
 
2.3.2. Taxanes  
Taxanes are widely known chemotherapeutic agents utilized in breast cancer treatment. The 
combination of the taxane, paclitaxel (taxol), and carboplatin is a mostly used combination 
routine for lung carcinoma [62]. Paclitaxel binds to β-tubulin and prevent MT 
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depolymerisation leading to a mitotic arrest followed by stimulation of caspase-dependent 
apoptosis by B- cell lymphoma (Bcl)-2 proteins. Taxanes often prolong the survival of 
patients with lung, breast, and ovarian carcinomas [63]. Like any other drugs, taxanes also 
have side effects these include myelosuppression, skin rash, peripheral neuropathy, and 
arthralgia. Subsequently adjunctive drugs are essentially used to minimize these side effects 
[64]. Efficiency of taxanes as adjuvant in the treatment of breast cancer is vivid. HER2 
signalling promotes numerous taxane-resistance mechanisms such as drug efflux and the 
metabolism of drugs [65]. A novel MT-stabilizing taxane called cabazitaxel (Jextana), which 
is effective on metastatic breast- and metastatic hormone-resistant prostate cancer also 
acquired paclitaxel and docetaxel resistance mechanism [66]. Cabazitaxel has side effects 
such as diarrhoea, neurotoxicity, vomiting, and nausea [67].  
2.3.3. Epothilones  
Mycobacterium Sorangrum cellulosum was discovered to have epothilones A and B as 
cytotoxic metabolites that steady the MTs. Epothilones are more toxic compared to taxanes in 
vitro, for instance, epothilone B is more cytotoxic to human ovarian cancer cells (OV-90) 
than paclitaxel [68]. Paclitaxel is competitively inhibited by epothilone B, as they both bind 
at a similar location on the β-tubulin. Taxanes, as well as epothilones, display different modes 
of resistance. Epothilones are effective against cancer cells that overexpress class III β-
tubulin, whereas resistance to taxanes arises when this class is overexpressed [68, 69]. The 
lactam analogue of epothilone B known as ixabepilone (Ixempra) was accepted in 2007 by 
USA for metastatic or locally advanced treatment of anthracycline and taxanes resistant 
breast cancer. This drug was the first amongst all epothilones to be accepted at clinical level 
[70]. The Ixabepilone is more metabolically stable and more clinically advanced epothilone 
with respects to its efficiency and tolerability in breast cancer patients. Ixabepilone toxicity is 
low in cell lines that express P-gp such as Madin-Darby canine kidney (MDCK) cells 
transfected with the human multidrug resistance (MDR)-1 gene and the kidney epithelial cells 
from the kidney of a pig transfected with the human MDR1 gene [71]. Ixabepilone is not a 
substrate of the breast cancer resistance protein (BCRP1), a protein that doxorubicin- and 
paclitaxel-resistant breast cancer cells (MCF-7 or breast adenocarcinoma /DOX and MCF-
7AX) significantly express, this describes the effectiveness of ixabepilone in taxane-resistant 




2.3.4. Vinca alkaloid 
Primary vinca alkaloids were obtained from the Catharanthus roseus plant, originally from 
Madagascar. These alkaloids were discovered to be active against cancer in 1960. In the year 
1963, vincristine was approved by USA for chemotherapy of cancer [72]. Such agents bind to 
the β-tubulin near the guanosine triphosphate (GTP)-binding location (the vinca domain) at 
the β-α-tubulin heterodimers interface. Attachment at the vinca domain inhibits the 
straightening of curved tubulin which consequently restricts the growth and assembly of MTs 
[73]. Vintafolide (EC145) has shown potency in treatment of ovarian and lung cancers in 
phase II of clinical trials. The vintafolide contains MT-destabilizing molecules, folic acid, 
desacetylvinblastine hydrazide, hydrophilic peptide spacer, and a disulfide-containing self-
immolative linker [68]. Vintafolide transports the MT-destabilizing molecules to the folate 
receptors (FRs) of FR-tumour cells. In different carcinomas, the FRs are overexpressed and it 
facilitates the up-take of folic acid-conjugated agents through a process called endocytosis 
[52]. The disulfide bonds are sliced and active desacetylvinblastine hydrazide diffuses in the 
endosome to the cytoplasm where they cause MT disturbance upon absorption of the 
vintafolides by the cell. The FRs are also expressed in small quantities in non-tumourigenic 
tissues, this makes vintafolide a supreme tumour target [73].  
2.3.5. Estrogen derivatives that target the MTs 
Estrogen helps during the development, diversity, and maintenance of numerous body tissues 
by stimulating the nuclear estrogen receptors (ERs), ER-α and ER-β, to trigger the activation 
of transcription factors [74]. Estrogen promotes proliferation and invasion, in breast and 
ovarian cancers. The sole purpose of the use of anticancer agents derived from estrogen is to 
contest with estrogen for the ER binding by antagonistic behaviour. The fulvestrant 
(ICI182780), is one instance of these compounds and has shown predominant effectiveness 
compared to the tamoxifen, which is currently a non-steroidal anti-estrogen agent used as 
standard hormone therapy in breast cancer [75]. 
2.3.6. The resistance of cancer cell against antimitotic agents 
Resistance towards antimitotic agents takes place in different phases of the therapy. An 
understanding of this resistance mechanism is crucial in the design of new antimitotic drugs 
[68]. Hereditary variations that occur preceding the cancer therapy are the initial source of 
therapeutic failure is called intrinsic resistance. Drug treatment leads to a secondary or 
acquired resistance. Tumour cells have a system of membrane efflux pumps belonging to the 
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ATP-binding cassette (ABC) family. They have been shown to develop these efflux pumps 
against chemotherapy involving antimitotic drugs in vitro [76]. Production of P-gp is 
facilitated by MDR1, which effluxes numerous hydrophobic antimitotic agents (vinca 
alkaloids and taxanes). Vinca alkaloids are transported out of the cell via the multidrug-
associated protein-1 (MRP)-1. The MRP2 and MRP7 export the taxanes and epothilone B is 
solely transported by MRP7 [68]. The expression of these efflux pumps displays some 
relationship with the poorer reaction toward antimitotic chemotherapy on prime tumours. 
Therefore, emerging drugs which are not P-gp substrates, for example, epithilones from 
second- and third-generation as well as taxanes with structural variations enabling them to 
dodge P-gp, are vital for combating difficulties of cancer resistance [77]. An alternative 
approach is to utilize molecules with activities that are enhanced by overexpression of P-gp 
efflux pumps. Reports suggest that when the paclitaxel drug and the P-gp inhibitor verapamil 
are used in combination, they have a synergistic cytotoxic effect against MDR breast cancer 
cell line (MCF-7/ADR) by in vitro. Within the tumour cells, mutations in the p53 gene, 
activation of phosphatidyl-3-phosphate kinase (PI3 K) and mutations within Ras/Raf genes, 
result in increased resistance to antimitotic compounds [68].  
The hypomethylation of phosphatase as well as tensin homolog removed from 
chromosome 10 (PTEN), a tumour suppressor gene, weakens the gene’s effect. This results in 
upregulation of PI3 K or Akt kinase (Akt) pathway. This substantially stimulate Akt, a 
protein controlling the anti-cell death proteins as well as the entry to the cell cycle. The loss 
of PI3 K regulation promotes an undesirable phosphorylation, leading to the pro-apoptotic 
protein deactivation as well as protection of the mitochondrial membrane from any 
disturbance [76]. This triggers an intrinsic mechanism which further increases the resistance 
towards apoptosis. When the mitogen-activated protein kinase cascade (MAPK) pathway is 
overexpressed, MAPK is activated by Ras (a small GTP kinase receptor), which 
consequentially leads to the Raf stimulation [68]. Mutations in the genes that upregulate this 
pathway result in survival signalling. The overexpression of class III β-tubulin isotope, an 
indicator utilised during the diagnosis of solid cancerous tumour for example cancer of 
ovaries, is assumed to be responsible for resistance against paclitaxel. The class III β-tubulin 
increases the instability in MT dynamics, in addition, counteracts the taxanes stabilizing 
action and it influences the vinca alkaloids efficiency [73]. The class III β-tubulin is also 
expressed in stressed cells and in O2 as well as nutrient deprived cells. The MT regulating 
proteins for example tau, stathmin, and mitotic centrosome associated kinesin (MCAK), are 
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all connected to antimitotic drug resistance. The SAC protein deregulation by gene 
amplification, for example, deregulation of Aurora kinase protein by the Aurora-A 
amplification also confers resistance to drugs targeting MTs [78].  
2.4. Drug resistance mechanisms 
Drug resistance is whereby cells/microbes acquire tolerance against the administered drug. 
However, comparable mechanisms have transpired in some other diseases such as cancer 
[65]. Certain mechanisms of drug resistance are specific to a particular disease, whereas 
others, for instance, drug efflux, witnessed in microorganisms as well as cancers that are 
resistant to drugs in humans, are evolutionarily well-maintained [53]. Numerous types of 
cancer were at first sensitive to chemotherapeutic agents. However, after a certain period, 
they became resistant via these mechanisms in addition to others (Table 1), including 
mutations of DNA and alterations in metabolism promoting drug inhibition as well as 
degradation (Fig. 4) [49].  
 
 
Figure 4: The outline of the methods that enable or stimulate drug resistance in the tumour  
     cells of humans that are either direct or indirect. Such methods can act either  
     individually or in conjunction and via several signal transduction mechanisms [49].   
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Table 1: The summary of chemo-resistance mechanisms [79]. 
Mechanism of Chemo-resistance 
The Uptake of Drug  During the administration of cytotoxic agents, the transporters of the superfamily 
of solute carriers (SLCs) have a crucial role. Alterations in the expression of these 
transporters, tumour cells are unable to absorb anticancer agents resulting in the 
development of resistance. 
The Export of Drug  Another major cause of resistance occurs when the ABC protein members are 
overexpressed, for example, the multidrug resistance protein 1(MDR1, ABCB1 
gene). It pumps out toxic agents and restricts the intracellular concentration of 
cytotoxic agents. 
Inactivation of Drug or 
Metabolic Activation of Pro-
Drug  
Any changes disturbing the metabolism of the drug results in the resistance. Such 
as tumour cells that overexpress phase I and II detoxifying enzymes having 
improved capacity to deactivate cytotoxic drugs. Increased activity of CYP3A4, an 
enzyme belonging to the family of cytochrome P450, deactivates such as 
paclitaxel in colorectal cancer cells. Moreover, reduced expression of drug 
activators resulted in decreased drug sensitivity, for example, carboxylesterases, 
typically involved in intracellular irinotecan stimulation, is reduced in cancerous 
cells with greater irinotecan resistance. 
Molecular Targets Changes Variations in molecular targets and malfunctioning signalling pathways are 
changing the sensitivity of a tumour towards the anticancer agents. For instance, 
the anthracyclines mechanism is based on their capacity to interact with DNA 
topoisomerases. Mutations in the TOP1 gene, encoding topoisomerase 1 resulted 
in a reduced capacity of anthracyclines to interact with their target. 
DNA Repair The capacity of a tumour to mend the DNA damage that was induced by the drug 
results in resistance for example repair of excised nucleotides caused by alkylating 
agents use. The mismatch repair (MMR) corrects wrongly matched nucleotides. 
Loss of MMR capacity results in genetic instability with greater resistance to 
different anticancer agents. 
Modifications in the Pro- and 
Anti-Apoptotic Balance 
Modifications of the programmed cell death key factor, for example, p53 has an 
important role in chemo-resistance. The BAX role is frequently reduced because of 
the mutation in this gene, resulting in the secretion of shortened proteins and 
growth of cells resistant to oxaliplatin. Upregulation and abnormal expression of 
antiapoptotic aspects, for example, Bcl-2 or Bcl-XL (B-cell lymphoma protein 
extra-large) are linked to enhanced resistance. 
 
One method of drug resistance against cancer includes decreasing the accumulation of 
drug by promoting the efflux (Fig. 5). The family members of ABC transporter protein are 
vital and allow efflux, these are intensively investigated regulators found in the plasma 
membranes of a healthy cell. The ABC carriers are trans-membrane proteins found in the 
cells of humans, exist in all phyla, and they move different molecules across the cell 
membranes [80]. However, the transporter structure differs amongst proteins and is classified 
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based on the existence of two different domains known as the extremely conserved 
nucleotide binding domain and the extremely mutable transmembrane domain. Upon the 
attachment of a certain substrate to the transmembrane area, on the nucleotide binding 
domain, ATP hydrolysis initiates an alteration in the structure that thrusts the substrate from 
the cell [81]. This efflux system has a crucial function in stopping excessive growth of toxins 
in the cell. The ABC carriers are extremely expressed in the liver as well as intestine 
epithelium, a site where proteins defend the body by means of pumping drugs and toxic 
substances into the intestinal lumen as well as bile duct. The ABC transporters also have a 
huge role in the sustenance of blood-brain barrier. Efflux through ABC carriers is a known 
method of drug resistance in tumour cells and a regular physiological process [49]. Three 
transporters such as BCRP, MDR1, and MRP1 are involved in most cancers that are drug 
resistant. These three carriers have a wide substrate specificity and efflux xenobiotics such as 
anthracyclines, kinase inhibitors, epipodophyllotoxins, taxanes, and vinca alkaloids from the 





Figure 5: The Illustration of the main pathways leading to the development of drug  






2.5. Next generation: improvement to existing therapies and novel cellular targets 
2.5.1. Protein kinases as potential drug targets for cancer chemotherapy 
Protein kinase (PK) defines the process of the enzyme which catalyses the transference of 
phosphate from the donor to the amino acid residue that is an acceptor in a substrate made up 
of multiple peptides. The consequential covalently modified structure of this peptide results 
in the target protein having new pharmacological properties [82]. Following the receptors that 
were coupled with the G-protein, PKs are currently promising drug targets (Fig. 6). Studying 
the major roles of the PK that contribute to cancer development, made pharmacologists to 
focus on targeted therapies as an ideal approach in blocking the evolution of cancer. Kinases 
are recognized as significant intracellular signalling components. For de-phosphorylation and 
phosphorylation to occur in a cell, protein kinases should be activated and/or inactivated [83]. 
The kinases can be grouped into two types the serine/threonine kinases and tyrosine kinases. 
The serine/threonine kinases phosphorylate the substrate on the tyrosine residues, whereas the 
tyrosine kinase recognizes the substrate molecule via the substrate-recognition site as well as 
the transfer of a phosphate molecule from ATP to the residues of the bound protein substrate 
at a nearby site known as ATP-binding or catalytic site [9].  
 
Figure 6: Proteins involved in mitosis as antitumor drug targets [84]. 
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The calmodulin antagonist (Naphthalenesulfonamides) was the first synthesized ATP-
competitive inhibitor of the kinase protein. Modification of this calcium binding protein by 
replacement of naphthalene with isoquinoline exhibited some PK inhibition. However, non-
specificity and efficiency of this drug only at high concentration was a serious disadvantage 
[85]. Staurosporine was then discovered, this drug was capable of inhibiting the PK C, which 
is a serine/threonine kinase type, which activates the Raf-MAPK as well as the NF-κB 
signalling system. However, lack of specificity was still a major drawback. More derivatives 
of staurosporine with some chemical changes and with specificity were synthesized, for 
example, 7-hydroxy (UCN -01) and N-benzoyl (PKC412) staurosporine, and they both are in 
clinical trials (Table 2) [86]. The UCN-01 blocks G2 from progressing to M in a cell cycle 
via checkpoint control kinase (CHK1) inhibition. Rapamycin initially discovered as an 
antifungal drug exhibited promising activity as an anticancer agent and was the first drug to 
be accepted for clinical trials because it specifically inhibited a single PK. The PKC412 is 
now used in the treatment of final stage of cancer [84]. 
Table 2: Kinase inhibitors and their targets [86]. 
Inhibitor Targeted kinase 
UCN-01, PKC412 
(Ser/Thr Kinase) 
Analogue of staurosporine and they target the 
PKC, CHK1, KIT and PDGFR 
Rapamycin or Sirolimus 
(Ser/Thr Kinase) 
An immunosuppressant that targets the mTOR 
or FRAP by binding to the FKBP 
CCI-779 or Temsirolimus and RAD001 (Ser/Thr 
Kinase) 
An ATP-competitive small molecule inhibitor 
that targets the p38 MAPK 
PD184352/CI-1040, PD0325901 and ARRY-142886 
(Ser/ Thr and Tyr Kinase) 
Inhibitors that are not ATP-competitive small 
molecule targeting the MEKK1/MEK1 
Trastuzumab/Herceptin (Tyr Kinase) A humanized monoclonal antibody targeting 
HER2/neu/ErbB2 
 
Due to the commercial success and clinical efficiency of the present drugs binding to 
the MTs, many research studies were conducted to further improve the potency of these drugs 
[87]. This has been successful with new and altered drugs such as epothilone and ixabepilone. 
These altered/new drugs are active against βIII-tubulin, which is an isotope that is not 
subjected to efflux via ABC-encoded P-gp. Whereas, a novel design of paclitaxel with 
albumin gives lower toxicity. Emphasis points to new routes of intervention in mitosis 
process that overcome limits involving drugs that target MTs, by having activity against 
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targets that are more specific. The one possible approach is targeting the kinase and kinesin 
family members since they are initiators of the phosphotransfer cascades that are essential for 
the signal transduction [88]. Presently, PKs appear as one of the essential classes of 
oncological drug targets. The kinases contribute to the biology of cancer via three different 
mechanisms such as (1) they either occupy the main roles in the oncogenic signalling 
cascades, (2) aid in development as well as the formation of cancer and (3) through 
mutationally induced kinases that may themselves trigger oncogenic changes. Interference 
with the last mechanism is a verified approach for therapeutic intervention. The Aurora 
kinase, as well as polo-like kinase, are the most studied targets amongst the kinases in the 
process of mitosis [89]. 
2.5.2. Aurora kinase 
One intensively studied kinases is the Aurora family; with three members that exist in 
humans, Aurora A, B, and C. Their key role is to accurately align and segregate 
chromosomes to make sure that the genomic integrity is maintained throughout the mitosis 
process [90]. Aurora A critically regulates the timing of entrance to mitosis, centrosome 
maturation, and plays a certain role in spindle assemblage as well as centrosome division via 
the kinesin motor protein KSP phosphorylation. In the early stages of mitosis, Aurora B 
regulates proteins that affect dynamics of the MT spindles throughout the spindle 
development, then encourage proper alignment of chromosomal kinetochore adherence in the 
mature spindle as well as regulate the spindle checkpoint [89]. In the final phases of mitosis, 
Aurora B assists in spindle cleavage furrow development, essential for the positive 
completion of cytokinesis. The role of Aurora C is not as well outlined as Aurora A and B, 
though it can overlap with Aurora B. Inhibitors with pan-Aurora specificity or selectivity for 
either Aurora A or Aurora B are currently in clinical trials (phase 2) [91]. 
2.5.3. Polo-kinase (PLK) 
There are five members of polo-kinase (PLK1 to 5) found in humans. In mitosis, PLK1 is 
extremely expressed and known to be pivotal in the regulation of several important 
procedures during the cell division, this includes controlling the entrance to mitosis and 
centrosome maturation, allowing division of duplicated chromatids via phosphorylation of 
cohesion as well as kinetochore dynamics initiating anaphase [92]. The PLK1 have some 
roles in the cytokinesis, resulting in mitotic exits, such as regulation of the kinesin motor 
protein MKLP2 in cytokinesis and phosphorylation of enzyme complexes found in cleavage 
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furrow formation. Over-expression of PLK1 is also apparent in many tumours and associated 
with poor diagnosis, and is connected to its capacity to negatively control the significant 
tumour suppressor p53. Intrinsically, a substantial mitotic controller, PLK1 has appeared to 
be a significant prognostic and therapeutic oncology target, with quite a few inhibitors 
currently in stage 2 of clinical trials [89].  
2.5.4. CDK and their role in mitosis 
There are 21 CDKs that are encoded in a human genome, and only CDK1-4, 6, 10, 11 seem 
to have some role in the progression of cell cycle. The rest have indirect functions such as 
activating other CDKs, regulating the transcription process or contain the neuronal 
responsibilities (CDK3, CDK7-9 and CDK5 respectively) [93]. The expression of CDKs 
changes during different cell cycle phases. CDK/Cyclin D complexes are active in G1, they 
also phosphorylate the retinoblastoma (Rb) protein enabling the progress of G1 to S phase. In 
the G1-S interface, Cyclins A and E accumulate and activate CDK1 and 2 consecutively, 
allowing further movement to the G2 stage. During this process, the cyclin B members 
(CDK1, cyclin B1) are the ones driving the cell to the mitosis [94]. In mammalian cells, 
proliferation becomes independent of growth factors as well as mitogens at the G1 restriction 
point (R) (Fig. 7). The Rb is a tumour suppressor that prevents proliferation via binding to the 
E2F family of transcription factors, thus suppressing their activities. Hence, the Rb pathway 
regulates the restriction point that maintains the regulation of cellular proliferation. 
During the early G1 phase, under unfavourable conditions for proliferation, cyclin D 
levels rise via posttranscriptional as well as transcriptional pathways [95]. High levels of D-
type cyclin drive the development of active kinase heterodimers with CDK6 and 4 catalytic 
subunits. Dynamic CDK4 and CDK6 then phosphorylates Rb partially relieving suppression 
of E2F to allow expression of genes required for the passage through the restriction point. 
This also involves the expression of E-type cyclin, which triggers CDK2 resulting in Rb 
hyper-phosphorylation completely freeing the E2F suppression, enabling the cells to exit G1, 




Figure 7: The regulation of mammalian cell cycle via the CDK4 and CDK6-cyclin D1-Rb- 
     p16/ink4a pathway [96]. 
 
2.5.5. Small molecule inhibitors of CDK as cancer chemotherapeutic agents 
Numerous inhibitors of CDK have been synthesized as potential anticancer agents in the past 
two decades, and these inhibitors have been evaluated against different types of tumours. 
[97]. Different chemical groups, characteristically the planar five-membered aromatic 
moieties such as indolinone, indirubin, thiazole, and flavonoids were characterized as small 
molecule ATP-competitive (type 1) inhibitors of CDKs. Most were active inhibitors of 
CDK1/2 because their structures were designed based on studies made on the monomer 
CDK2 [96]. The first synthesized group of CDK inhibitors were non-selective and are now 
referred to as pan-CDK inhibitors, these include the flavopiridol (Fig. 8). The flavopiridol 
showed a broad spectrum of activity (inhibited CDK1, 2, 4, 6, 7 and 9). This drug can trigger 
the cell cycle arrest at G1 and G2 phase; however, it can also trigger a response that is 
cytotoxic, this may be because of the inhibition of CDK7 and 9 that results in transcriptional 
suppression [97]. The second group of CDK inhibitors were synthesized with the aim of 
increasing the selectivity of the drug, these include dinaciclib. This potent inhibitor of CDK1, 






Figure 8: CDK inhibitors targeting different phases of the cell cycle [96]. 
In a cell-based assay, Dinaciclib inhibited substantially Rb-stimulated 
phosphorylation process. This drug also inhibited the progression of cell cycle in addition to 
triggering regression on solid tumours. AT7519, a pyrazole 3-carboxyamide compound 





Figure 9: The first and second generation CDK inhibitors [97, 98].  
2.5.6. Agents influencing MT dynamics: KSP 
Eukaryotic cells have numerous types of molecular machines essential in organising the 
cellular structure and in the direct intracellular movement. They are grouped into 3 super-
families of proteins the dynein, myosin, and kinesin [99]. They all use ATP hydrolysis to 
yield a coordinated force on MTs to execute their roles. Kinesins are composed of the 
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superfamily of about 650 distinct MT-dependent motor proteins, up until now found solely in 
eukaryotes. There are fourteen families under kinesin family grouped based on phylogenetic 
analyses of their characteristics motor domains of 330– 440 residues in size [89]. They are 
structurally diverse having minor sequence conservations. The motor domain is located at the 
C-terminal (C-type kinesins) or N-terminal (N-type kinesins) or inside (kin 1/M-type 
kinesins). The N-terminal travel to the plus–end of microtubulin (β-tubulin) while C-type 
kinesins move towards the minus–end (α-tubulin) of the MT. The M-type kinesins move 
differently because they diffuse toward the end where they display depolymerisation action of 
MT [100]. 
The conventional kinesin KHC, Kif5B, Kif5s, kinesin-1 family, were the first kinesin 
to be discovered. This kinesin is found abundantly as a protein dimer in the human body, 
containing heavy linkers that are identical and conjoined via a couple of light chains. There 
are three distinct domains within a prototypical N-type kinesin (Fig. 10) [101]. 
 
Figure 10: The structure of the N-terminal conventional kinesin [89]. 
The motor domain contains the pockets where nucleotides bind and regions where MTs 
interact, and lastly the region that has the neck to neck linker. The linker joins the motor 
domain to an inner region of the α-helical, thus creating a helical coil responsible for 
oligomerisation into dimers or complex oligomers. Next is the C-terminal tail domain, direct 
or indirect cargo interactions occur in this terminal. This site gives kinesins various roles 
across transport, mitosis, and meiosis [89]. 
KSP or Eg5 is a kinesin superfamily member of the molecular motor proteins. 
Inhibition of KSP stops the spindle pole from separating, leading to a lengthy mitotic arrest 
during the pro-metaphase and consequent cell death. Furthermore, the adult peripheral 
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nervous system does not express KSP; hence agents that inhibit KSP may not result in side 
effects that are neuropathic [99]. Agents inhibiting KSP influence the development of cancer 
cells that are resistant to Taxol. KSP is one of the validated therapeutic targets of choice for 
many cancers. Inhibitors of kinesin responsible for mitosis can be applied broadly in the 
treatment of other proliferative illnesses like lymph proliferative disorders found in patients 
suffered from an autoimmune disease. Moreover, it is found abundantly in the proliferating 
tissues of humans and over-expressed in the uterus, lung, ovary, breast, and colon [100]. 
Although KSP is expressed in post-mitotic nerve cells in rats, it was not detected in human 
nerve cells. Thus, KSP has emerged as an attractive target for new cancer therapies that could 
avoid the neuropathic side effects caused by taxanes and vinca alkaloids. In addition, KSP 
inhibitors have demonstrated activity against taxane-resistant tumour cell lines, further 
supporting their potential value in treating refractory human cancers [88]. Agents with the 
ability to inhibit KSP can arrest cells undergoing mitotic process only and these agents are 
expected to be able to distinguish between proliferating and non-proliferating cells. Hence, 
these inhibitors will not contain severe side effects related to the ones of the antimitotic 
agents. Efforts have been made in developing agents that are able to inhibit KSP in previous 
years after monastrol, the first inhibitor of KSP that uses monopolar spindles to arrest mitosis 
[102].  
Many KSP inhibitors have progressed into clinical trials and many others are in 
preclinical studies. In search of novel KSP inhibitors, ligand-based design strategies 
(pharmacophore-model and 3D QSAR) and structure-based (docking) or integrated 
approaches (Interaction based-pharmacophore models) were reported in the literature [103]. 
The protein data bank (PDB) has the deposit of about 45 X-ray solved crystal structures for 
the ligand-bound kinesin-like proteins. Among them, recently reported eight PDB structures; 
4BXN, 3L9H, 4A5Y, 3CJO, 2Q2Y, 2Q2Z, 2FKY, and 2FL2 carrying different inhibitors 
bound to the active-site of KSP. The KSP structure is made up of 1057 residues and is 
separated into three spheres (Fig. 11). A short 20-residue-long stretch precedes the motor 
domain, which ranges from residue Val21 (β1 sheet) to the RAK motif in the α6 helix. The 
motor domain hydrolyses ATP for energy production and for proteins transport across the 
fibres of the MT [84]. A short linker (Asn358-Pro363) integrates the motor to the stalk region 
(Glu364-Val523, Cys684-Lys716, and Gln782-Arg826). The KSP tail domain (residues 
Tyr829-Leu1057) has a potential site for p34 phosphorylation (Thr927 in human). For 




Figure 11: KSP structure solved through X-ray crystallography [104]. 
In 2007, Liu et al., developed a quantitative three-dimensional pharmacophore model 
with a correlation coefficient of 0.965 based on 25 inhibitors of KSP [105]. They reported the 
best hypothesis (Hypo1) bearing four chemical characteristics (one hydrogen-bond acceptor, 
one hydrogen-bond donor, one aromatic ring and one hydrophobic) which were computed via 
HypoGen module implemented in Catalyst software package. In the same year, Jiang et al., 
reported docking (structure-based) studies of 15 KSP inhibitors and proposed the significance 
of ‘minor pocket’ at the binding-site other than the existence of ‘main pocket’. As per their 
study, a linear correlation was observed between pIC50 values of the compounds and lowest 
binding free energies computed from the docking simulation which described the role of 








Figure 13: Binding mode of KSP inhibitors at minor binding pocket mainly surrounded by  
         Ala218 and Arg221 [105]. 
Recently, Nagarajan et al., reported the combined ligand- and structure-based 
approaches to identify novel KSP inhibitors. In their study, they developed seven interaction-
based pharmacophore (IBPs) models using six crystal structures of KSP bound with 
diversified ligands followed by validation of 16 structures. The developed models were 
applied to filter the ChemDiv database (0.7 million) with the hits being passed to an in silico 
docking protocol. The IBP-based hits were subjected to docking (GOLD and GLIDE) 
subsequently compounds sorted based on the Gold fitness or Glide score [100]. Authors 
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extended the research approach from computational work to biological screening including 
inhibition of tumour cell proliferation, basal KSP ATPase activity and phenotypic analysis of 
selected inhibitors. By these integrative approaches, authors identified and developed small 
molecules as novel KSP inhibitors (Fig. 14).  
 
 
Figure 14: Interaction-based pharmacophore and docking in the identification of novel KSP  
         inhibitors [107]. 
Carbajales et al., analysed KSP allosteric binding-site, including 24 crystal structures 
of KSP-allosteric inhibitor and developed planar heterocycle structure based on X-ray crystal 
structure of the protein (PDB ID: 2GM1). This structure-guided design was followed by 
multicomponent reaction and functional characterization in enzymatic, cell assays resulted in 
the detection of novel inhibitors of KSP having anti-proliferative activity [99]. Recently 
(2015), Yokoyama et al. reported for the first time the X-ray crystal structure and 
biochemical studies on the KSP motor domain in complex with a new type of allosteric 
inhibitor (PVZB1194). This biphenyl-type inhibitor was proposed to bind with the α4/α6 
allosteric pockets 15 Å from the pocket that binds ATP, which varies from traditional 





Figure 15: The structure of the KSP-ADP-BI8 complex (pink) was superimposed onto that  
         of the KSP-PVZB1194 complex (yellow). PVZB1194 are shown as orange sticks,  
         and two BI8 (BI8a and BI8b) and ADP are shown as purple sticks. A blue arrow  
         indicates Glu304 Cα displacement from KSP-ADP-BI8 to KSP-PVZB1194. A  
         red arrow indicates Leu324 Cα displacement from KSP-ADP-BI8 to KSP- 
         PVZB1194. Dotted ellipses show neck-linker regions [102]. 
 
However, thiazole-containing inhibitors are also reported to compete with ATP but 
not with MTs, while biaryl compounds antagonize ATP interactions. The major common 
adverse effect associated with KSP ATPase inhibitors is neutropenia. While, ispinesib 
resistance was observed in some clinical trials [102]. Preclinical studies indicated that 
ispinesib is predicted to be a substrate for drug resistance. Mutation in the binding pocket is 
another origin of drug resistance. An alteration of the L5 pocket of KSP could offset the 
action of ATP non-competitive inhibitors binding to it. It may probably due to multidrug 
resistance that is the major barrier for many anticancer drugs. Development of ATP 
competitive KSP inhibitors binding to ATP binding-site (Fig. 16) can overcome mutation-





Figure 16: ATP binding-site highlighted in KSP-(S)-monastrol complex [105]. 
Based on these literature reports, it was motivated to take up the proposed investigation 
involving the development of small organic molecules as KSP inhibitors [109]. 
2.5.7.  KSP inhibitors under clinical evaluations  
Ispinesib, a quinazoline-based agent is the most studied KSP inhibitor. (Table 3) [54]. 
Ispinesib was evaluated against different types of solid tumours in combination with other 
therapeutic agents [110]. Combinations of ispinesib with conventional carboplatin as well as 
docetaxel have been tried, but, there were no observable synergic effects. Ispinesib has been 
found to moderately inhibit the cytochrome P450 (CYP) metabolic enzyme CYP3A4, which 
would contraindicate combination with numerous existing drugs [111]. Many KSP inhibitors 
have progressed into clinical trials and many others are in various stages of preclinical 
studies. Recently, KSP inhibitors of wide structural diversity have appeared in literature 
including six-membered heterocycle scaffolds [dihydro-pyrimidine derivative (Monastrol), 
quinazolinone derivatives (Ispinesib and CK-0106023), flavones, isoflavones, quinazolin-
thione derivative (dimethylenastron), isoquinolines, and benzimidazoles], five-membered 
heterocycles (dihydropyrazoles, dihydropyrroles, thiophenes, dihydrothiadiazoles, thiazoles, 
and fused pyrroles), biaryl compounds (GSK-1 and GSK-2), natural products (adociasulfate-
2), and second-generation KSP inhibitors benzopyranone derivative (SB-743921) [112]. The 
mechanism of actions of most of the KSP inhibitors include binding to KSP as well as 
inducing conformational changes that are both local and distal allowing ATP to bind while 
preventing the release of adenosine diphosphate (ADP). Some of the potent molecules acting 
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as KSP inhibitors under clinical and preclinical development are presented in Table 3 and the 
structures of active compounds are illustrated in (Fig. 17) [104]. 
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Figure 17: Known potent KSP inhibitors under clinical or preclinical trials [104]. 
2.6.  Chemistry and pharmacological properties of 1,3,4-thiadiazoles 
Thiadiazoles are dominant and significant heterocyclic structures that are five-membered ring 
with sulphur (S) and two nitrogen (N) atoms [113]. Moreover, thiadiazoles are comprised of 
numerous isomers such as, 1,3,4-thiadiazole, 1,2,5-thiadiazole, 1,2,4-thiadiazole, and 1,2,3- 
thiadiazole. Amongst the above mentioned thiadiazoles, the 1,3,4-thiadiazole (Fig. 18) was 




Figure 18: The different isomers of thiadiazoles [115]. 
Due to the inductive effect of elemental sulphur, 1,3,4-thiadiazole is regarded as a base that is 
very weak and it displays great aromaticity. The 1,3,4-thiadiazole ring cleaves in the aqueous 
base but becomes stable in an aqueous acid [116]. The 1,3,4-thiadiazole is comparatively 
inactive towards electrophilic attack, and seems to be sensitive to the nucleophilic attack. 
Introduction of substituents at position C2 or C5 makes the ring highly active and to yield 
compound libraries. Therefore, the above-mentioned properties make the 1,3,4-thiadiazole 
derivatives ideal candidates for applications in different fields. The 1,3,4-thiadiazole 
analogues are reported to exhibit versatile applications in the fields of pharmacy, medicinal 
chemistry, agriculture, and materials chemistry [117]. They have shown potent anticancer 
[118], antiviral [119], antifungal [120], analgesic [121], anti-inflammatory [122], antiparasitic 
[123], antitubercular [124], and antioxidant [125] activities. Furthermore, 1,3,4-thiadiazoles 
are reported to have a role in the management of central nervous system disorders, such as 
convulsions and mental depression. In addition, they can inhibit mitotic enzymes such as 
KSP and other kinases. Similarly, these thiadiazoles have shown efficacy against various 
cancer cell lines such as human hepatocellular carcinoma cell line (HepG2), human breast 
cancer cells MCF-7 and human lung cancer cells A549 [126]. 
1,3,4-Thiadiazoles such as methazolamide (MZA), benzolamide (BZA) as well as 
acetazolamide (AZA) (Fig. 19) are well known for their carbonic anhydrase (CA) inhibition 
devoid of high CA II to CA IX selectivity during cancer therapy [110]. The thiadiazole ring is 
different when compared to that of the thiadiazoline as well as thiophene in that it partakes in 
the interaction of H-bonds via the CA active site. 1,3,4-Thiadiazoles hybridized with 1,4- 
benzodioxan were exhibited good inhibition than the reference drug staurosporine, while few 
other derivatives showed competitive anticancer potential towards the SW1116, HELA, 
BGC823 as well as HepG2 cell lines [127]. The molecular docking results showed that the N- 
of thiadiazole ring formed the H-bond with the Gly505 -NH, this might have contributed to 





Figure 19: Sulphonamide-1,3,4-thiadiazole hybrids as CA inhibitors [110]. 
The 1,3,4-thiadiazoles exhibited a wide range of anticancer activities towards human 
cancer cells in addition to targeted molecular processes involved in proliferation, survival, 
and metastasis together with the CA, matrix metalloproteinases (MMPs), histone deacetylase 
(HDACi), Bcl-2, Bcl- XL, Bcl-2-associated X protein, Akt/PKB, tubulin, focal adhesion 
kinase (FAK) and protein tyrosine kinases [106, 110, 129]. The ring of 1,3,4-thiadiazole is 
effective against cancer cells because of the two nitrogen atoms having a great electron-
donating capacity to chelate with some metal ions or co-enzymes. Moreover, the introduction 
of different atoms/groups, for example, chloride (Cl) via substitution to the carbon (C) 
number 2 and 5 in the 1,3,4-thiadiazole increases the anticancer activity of this scaffold. 
Rizzo et al., computed the binding affinities (MM-GBSA and MM-PBSA) as well as the 
selectivity of 5-substituted-1,3,4-thiadiazole-2-thiones against two particular MMPs 
(gelatinase-A and stromelysin-1). It was shown that thiadiazoles selectively inhibit 
stromelysin-1 more than gelatinase-A [110]. 
The 2-(4-fluorophenyloamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole (FABT) 
reduced the cell proliferation of the major cell lung cancer A549, this might be because of the 
inhibition of ERK1/2 kinase pathway. This showed that FABT inhibits the phosphorylation 
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of the protein without affecting the gene expression. Furthermore, 2-(4- chlorophenylamino)-
5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole (4ClABT) reduced synthesis of DNA, prominent 
variations in the morphology of a tumour and the decreased motility of cells. The 1,3,4-
thiadiazole hybrids containing methoxyphenyl or p-hydroxyphenyl have high activity in 
HDAC inhibition as well as anti-proliferation against carcinoma cells of Ehrlich ascites 
[111].  
2.7.  Chemistry and pharmacological properties of thiazolones  
Thiazolone (Fig. 20) has been shown to be another pharmaceutically important scaffold. 
Thiazolones are well known for their diverse medicinal properties, for example, libraries of 
4-Thiazolidinone have continually attracted the interest researchers for years due to their 
diverse biological activities similar to that of thiadiazoles [130]. 
 
 
Figure 20: Structure of a simple thiazolone [130]. 
Some of the clinically used drugs such as thiazolidomycin, etozoline, ralitoline and 
pioglitazone (Fig. 21) bearing thiazolone pharmacophore in their chemical structures support 
the versatile applications of thiazolone moiety in therapy [131]. It is possible that the 
anticancer activity of 4-thiazolidinones correlates with their affinity to antitumor bio-targets, 
for example, antiapoptotic biocomplex Bcl-XL-BH3, JNK stimulating phosphatase-1 (JSP-1), 
integrin αvβ3 receptor and tumour necrosis factor (TNFa). For example, 5-arylidene-4-
thiazolidinone/ thiazolone is one of the pharmacophores present in many of the reported 
anticancer compounds, displaying activities against human breast cancer cell line MDA-MB-
231, paclitaxel-resistant H460taxR, non-small cell lung cancer cell line H460 and human 
colon cancer cell line HT29 [131]. These scaffolds have also proven to be potent CDK 
particularly CDK1 inhibitors. The antagonists of integrin αvβ3 showed to be ideal novel 
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antitumor drugs amongst three of the substituted 2-arylimino-4-thiazolidinones. The 2- 
phenylimino-3-alkyl-4-thiazolidinone hybrids inhibited the HT29 cell line, shown by over-
expression of cyclooxygenase-2 (COX-2), and inhibited CDK1/cyclin B. These activities 
were established by blocking G2-to-M progression in the cell cycle and by inducing apoptotic 
cell death [130, 131]. Derivatives of 5-benzylidene-4-thiazolidinone have antitumor activities 
containing diverse biotargets such as the non-membrane protein tyrosine phosphatase (SHP-
2), JSP-1, sphingosine kinase (SK), and phosphatase of a regenerating liver (PRL-3). 
Furthermore, these hybrids possess potent anticancer properties against the paclitaxel-
resistant H460taxR [132]. 
 
 
Figure 21: Drugs bearing thiazolone moiety [131]. 
2.8.  Design of the novel anticancer compounds by molecular hybridization 
Although there have been considerable developments in preventing and treating cancer by a 
number of approaches, the successful chemotherapy for many types of cancer remains a 
greater challenge till date. Therefore, it is very imperative to establish some novel, safe, and 
efficacious chemotherapeutic agents exhibiting the broad spectrum of anticancer properties to 
different cancerous tissues with devoid of host cell toxicity. Development of drug-resistance 
via mutations in amino acid sequence is the major issue commonly observed with the 
available chemotherapeutic agents during the therapy of cancer.  
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Rational drug design via molecular hybridization is still a useful and promising 
approach in synthesis and development of novel pharmaceutically active heterocyclic 
compounds. The recent continuous emergence of literature reports and patents in the field of 
pharmaceutical and medicinal chemistry evidenced that this strategy is successfully being 
adopted. 
The thiazolone moiety was proven to be one of the active pharmacophores present in 
the CDK inhibitors (Fig. 22). Similarly, thiadiazole-based compounds are potent inhibitors of 
KSP (Fig. 22). Interestingly, many of the available KSP inhibitors are not ATP-competitive 
inhibitors, rather allosteric inhibitors. Thus, newer and more selective kinase inhibitors can 
provide safe and effective treatment for various types of cancer [133]. Hence, we envisaged 
hybridizing the CDK inhibition moiety (thiazole) with KSP inhibition core (thiadiazole) to 
obtain a novel library of compounds exhibiting synergistic anticancer activities with dual 
mode of action. Such analyses may not only reveal the potency but also confirm the 
pathological events associated with the cancer progression and its control. We herein, report 
the synthesis and anticancer evaluations of twenty-two novel hybrid molecules bearing 1,3,4-





Figure 22: Thiadiazole and thiazolone scaffolds reported as KSP and CDK inhibitors.  
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3.1.  Synthesis and spectral studies  
The synthesis of a novel series of TDT hybrid compounds (8a-v) was accomplished using a 






Scheme 1: Synthetic route for novel of TDT hybrids (8a-v). (a) NH2CSNHNH2, MeOH, rt,  
     15h; (b) (CH3CO)2O, reflux, 2 h; (c) NH2NH2, MeOH, rt, 3 h; (d) ClCH2COCl,  
     N,N-DMF, rt, 2 h; (e) NH4SCN, EtOH, reflux, 2h; (f) ArCHO, NaOEt, rt, 1-2 h. 
 
Acetophenone (1) reacted with thiosemicarbazide under vigorous stirring conditions 
afforded (E)-2-(1-phenylethylidene)hydrazine-1-carbothioamide (2), quantitatively. The 
59 
 
structure of 2 was established based on 1H NMR in which the appearance of a singlet peak at 
δ 10.27 ppm was attributed to –NH proton. Moreover, the primary amino group (NH2) 
demonstrated one singlet at δ 8.26 ppm for one proton, while the other proton was merged 
with the aromatic region (δ 7.91 – 7.93 ppm). In 13C NMR, we observed a characteristic peak 
at δ 178.93 ppm which indicated the presence of C=S functionality. Compound 2 undergoes 
cyclization and subsequent acetylation using acetic anhydride yielded N-(4-acetyl-5-methyl-
5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)acetamide (3). The formation of compound 3 was 
confirmed by presence of additional methyl group protons as individual singlets at δ 2.19 
ppm and δ 2.28 ppm in 1H NMR and two new carbonyl carbons (C=O) at δ 167 and 169 ppm, 
respectively in 13C NMR. Nucleophilic displacement of acetyl group of 3 with hydrazine 
hydrate furnished compound 4 and was confirmed based on 1H NMR, where the amide NH 
disappeared and the prominent appearance of a new broad singlet at δ 4.11 ppm assigned to 
the protons of NH2 group. All these spectral data were corroborated with the literature 
reported data [1]. Reaction of 4 with chloroacetyl chloride in N,N-dimethylformamide under 
the mild basic condition (triethylamine) produced (4-Acetyl-5-methyl-5-phenyl-4,5-dihydro-
1,3,4-thiadiazol-2-yl)glycinoyl chloride (5) of 91 % yield. The 1H NMR spectrum of 5 
revealed the disappearance of broad singlet of the NH2 proton at δ 4.11 ppm and appearance 
of two informative singlets at δ 9.29 and 3.91 ppm, which are attributed to NH and methylene 
protons (CH2), respectively confirming the formation of 5. The heterocyclization of 5 in the 
presence of ammonium thiocyanate and ethanol under reflux conditions, efficiently yielded 2-
((4-Acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)thiazol-4(5H)-one 
(6), quantitatively. This was confirmed by the 1H NMR spectrum, in which singlet signals 
corresponding to NH and CH2 protons appeared at δ 12.18 and 4.06 ppm respectively. This 
has been further substantiated in 13C NMR which displayed a prominent signal at δ 173.99 
ppm accredited to C=O of thiazol-4(5H)-one moiety thus confirming the cyclization reaction. 
The compound 6 possibly exists in different tautomeric states and the theoretical pathway of 





Scheme 2: The tautomeric pathway for compound 6 [2]. 
To achieve quick access to the final compounds (8a-v) for pharmacological 
evaluation, a facile synthetic strategy was employed consisting of a well-known Knoevenagel 
reaction of 6 with the appropriate aromatic/heterocyclic aldehydes (7a-v). The structures of 
twenty-two newly synthesized hybrids (8a-v) were characterized based on their 
physicochemical and spectral (FT-IR, 1H NMR, 13C NMR and HR-MS) analysis. The 
analytical data of all the newly synthesized compounds along with their anticipated structures 
are summarized in the experimental section. 
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3.1.1.  FT-IR characterization 
Infra-red spectroscopy serves as an analytical tool in the identification of different functional 
groups in all the synthesized novel compounds. There is a consistent and prominent peak 
around 1663-1716 cm-1 indicated the presence of a carbonyl group (C=O) in all synthesized 
compounds. Similarly, a characteristic peak around 3661 – 3379 cm-1 attributed to the 
presence of NH in all the compounds. All synthesized compounds showed resemblance of the 
characteristic peaks in the FT-IR, which further confirmed the presence of the expected 
functional groups. In particular, 8h showed carbonyl (C=O) stretching bands at 1653 and 
1716 cm-1 as well as NH bond stretching at 3379 cm-1 established its formation (Fig. 23).  
 
Figure 23: The FT-IR spectrum of compound 8h. 
3.1.2.  1H NMR characterization  
In the 1H NMR of 8a-v, the absence of the singlet signal of methylene protons in thiazolone 
moiety and appearance of methine proton (=CH-) resonating in the range of δ 7.72 - 7.99 
ppm along with aromatic protons confirmed the formation of the final compounds. All the 
target molecules 8a-v exists as geometrical isomers (E and Z). The Z conformation of the 
exocyclic C=C double bond was assigned based on 1H NMR and literature data of reported 
analogous of 1,2,4-thiazolidinediones and 4-thiazolone [2, 3]. Specifically, the appearance of 
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methine proton in the deshielded region (> δ 7.72 ppm) adjacent to C=O of thiazolone ring 
displayed higher chemical shift values than the anticipated values for E isomers (< δ 7.5 ppm) 
which show lower chemical shift values, as they appear mostly in the shielded region [4]. 
Thus, confirming the Z conformation for all the final compounds (8a-v). Moreover, in the 1H 
NMR spectra, the NH proton of 8a-v was observed at the deshielding position and it 
displayed higher chemical shift values at δ 13.01-12.56 ppm. This indicated that the 
substitution is on the 2-position rather than on 3-position, and this pattern correlated with the 
lactam proton since an imine proton generally get affected by the shielding effect (about δ 9.5 
ppm) [5]. The 1H NMR characterization was better explained by illustrating an example of 
compound 8h. It is interesting to know that two singlets at δ 2.27 and 2.39 ppm 
corresponding to two methyl group protons. Also, characteristic broad singlet peak and a 
sharp singlet appeared at δ 12.9 and 7.88 ppm assigned to NH and arylidine CH, respectively. 
All this data confirmed the structure of the compound 8h (Fig. 24). 
 
Figure 24: The 1H NMR spectrum of compound 8h.   
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3.1.3. 13C NMR characterization 
These interpretations were further validated by recording their respective 13C NMR spectra. 
Where arylidene carbon of the final derivatives resonated in the range of δ 148.9 - 158.5 ppm 
in addition to the observed aromatic carbons evidently confirmed the formation of desired 8a-
v via Knoevenagel condensation. The 13C NMR of 8g showed a deshielded peak belonging to 
the arylidene carbon (δ 148 ppm) and an additional tolyl carbon that belongs to CH3 (δ 27 
ppm) at shielded region, which substantiated and established the structure of 8g (Fig. 25). 
 
Figure 25: The 13C NMR spectrum of compound 8g. 
3.1.4.  HRMS Analysis 
Moreover, the formation of final derivatives was confirmed by recording their respective 
HRMS, which displayed accurate molecular ion peaks that correlated with their expected 







Figure 26: The HRMS spectrum of compound 8a. 
3.2. Experimental (synthesis) 
All research chemicals (AR grade) were purchased from Sigma–Aldrich and Merck 
Millipore, South Africa. Solvents except laboratory reagent grade were dried and purified per 
the literature when necessary. The progress of reactions and purity of compounds were 
monitored by thin-layer chromatography (TLC) on pre-coated silica gel plates procured from 
E. Merck and Co. (Darmstadt, Germany) using methanol (10 %) in chloroform as mobile 
phase and iodine vapors as a visualizing agent. Compounds were purified by recrystallization 
technique using ethanol. Melting points of synthesized compounds were determined in 
Thermo Fisher Scientific (IA9000, Essex, Great Britain) digital melting point apparatus and 
are uncorrected. IR spectra were recorded on Bruker Alpha FT-IR Spectrometer (Billerica, 
MA, USA) by using ATR technique. The 1H NMR and 13C NMR were recorded on Bruker 
AVANCE 400 and 100 MHz (Bruker, Rheinstetten/Karlsruhe, Germany) using DMSO-d6 or 
CDCl3. Chemical shifts are reported in  ppm units with respect to TMS as an internal 
standard. HRMS were recorded on Autospec Mass Spectrometer under the electron impact at 




3.2.1. (E)-2-(1-phenylethylidene)hydrazine-1-carbothioamide (2) 
To a solution of acetophenone (33.3 mmol, 4g) and thiosemicarbazide (34.6 mmol, 3.15 g) in 
90 ml of methanol, 0.3 ml of concentrated hydrochloric acid was added slowly dropwise and 
stirred for 15 hours. After completion of the reaction (as monitored by TLC), 30 ml of water 
was added to the mixture to obtain product 2. Thus, the obtained solids were filtered and 
washed with diisopropyl ether to yield white crystals of 2 in pure form (3g, 80 % yield). 1H 
NMR (400 MHz, CDCl3) : 2.29 (s, 3H, CH3); 7.37 – 7.39 (m, 3H, ArH); 7.91 – 7.93 (m, 2H, 
ArH, 1H, NH2); 8.26 (s, 1H, NH2); 10.2 (s, 1H, NH) ppm; 
13C NMR (100 MHz, DMSO-d6) 
: 13.9 CH3; 126, 128, 129, 137, 147, 178 ppm. 
3.2.2. N-(4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-
yl)acetamide (3) 
Compound 2 (0.889 mmol; 0.3g) in acetic anhydride (11 mmol; 1 ml) was refluxed till it 
became a homogenous mixture. Then, the solution was cooled to room temperature to obtain 
compound 3. Diethyl ether (120 ml) was added to remove non-polar impurities to yield white 
crystals which was dried under vacuum (0.25 g, 83 %). 1H NMR (400 MHz, CDCl3) : 2.01 
(s, 3H, CH3); 2.19 (s, 3H, CH3); 2.28 (s, 3H, CH3) ppm; 7.23 – 7.24 (s, 1H, ArH); 7.25 – 7.35 
(m, 4H, ArH); 11.6 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 22.4, 23.6, 26.5 
(3CH3); 78.5, 124, 127, 128, 142, 143, 167, 169 (2C=O) ppm.  
3.2.3. 1-(5-amino-2-methyl-2-phenyl-1,3,4-thiadiazol-3(2H)-yl)ethan-1-one (4) 
Compound 3 (3 mmol; 1 g) and hydrazine hydrate (13 ml) in 10 ml methanol was stirred for 
6 h. After completion, ice was added to yield white precipitates which were filtered and dried 
(0.83 g, 83 %). 1H NMR (400 MHz, CDCl3) : 2.15 (s, 3H, CH3); 2.34 (s, 3H, CH3); 7.17 – 
7.19 (m, 1H, ArH); 7.20 – 7.28 (m, 2H, ArH); 7.37 – 7.39 (m, 2H, ArH); 4.11 (s, 2H, NH) 
ppm. 
3.2.4.  (4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)glycinoyl 
chloride (5) 
To a stirred solution of 1-(5-amino-2-methyl-2-phenyl-1,3,4-thiadiazol-3(2H)-yl)ethan-1-one 
4, (0.02 mol, 4.7 g) and triethylamine (0.02 mol, 2.78 ml) in N,N-dimethylformamide (10 
ml), a solution of chloroacetyl chloride (0.024 mol, 1.91 ml in 10 ml DMF) was added 
dropwise. After addition, the mixture was stirred further for 2 h. Then, the mixture was 
poured onto the crushed ice to obtain a brownish precipitate, which was isolated by filtration, 
washed with water and dried. Purification of the crude product by 95% ethanol produced a 
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light-brown product 2 of 91 % yield (4.3 g); mp 188-190 C; 1H NMR (400 MHz, CDCl3) : 
2.20 (s, 3H, CH3), 2.31 (s, 3H, CH3), 3.91 (s, 2H, CH2), 7.17 – 7.36 (m, 5H, ArH), 9.29 (s, 
1H, NH) ppm. 
3.2.5. 2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-
yl)amino)thiazol-4(5H)-one (6) 
A solution of 6 (1 mmol, 0.311g) and ammonium thiocyanate (2 mmol, 0.152g) in 10 ml of 
98% ethanol was refluxed for 3 h. Upon completion of the reaction (as monitored by TLC), 
the solution was kept at room temperature and thus, the precipitates obtained was filtered, 
washed with water and dried. Recrystallization of the crude product with ethanol produced a 
grey coloured product 6 (82 % yield). mp 199-200 C; FT-IR (ATR, cm-1) max: 1740 (C=O), 
3114 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.23 (s, 3H, CH3), 2.37 (s, 3H, CH3), 4.06 (s, 
2H, CH2), 7.26 – 7.42 (m, 5H, ArH), 12.18 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-
d6) : 23.97, 27.01 (2CH3), 35.53 (CH2), 82.63, 124.50, 127.66, 128.49, 143.57, 149.40, 
165.72, 168.10, 173.99 ppm.  
3.2.6. General procedure for synthesis of (Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-
dihydro-1,3,4-thiadiazol-2-yl)amino)-5-arylidenethiazol-4(5H)-one (8a-v)  
A well-stirred solution of 6 (1 mmol) in 5 ml of ethanol was basified with a catalytic quantity 
of sodium hydroxide (half-pellet). Appropriate aldehydes (7a-v) (1 mmol) were then added to 
the solution and stirred further for 1-2 h. After completion of the reaction (as monitored by 
TLC), the solution was buffered with dilute hydrochloric acid dropwise under cold condition. 




Yellow crystals; yield: 70 %; mp 211-212 C; FT-IR (ATR, cm-1) max: 1711 (C=O), 3693 
(N-H); 1H NMR (400 MHz, DMSO-d6) : 2.33 (s, 3H, CH3), 2.40 (s, 3H, CH3), 7.28 – 7.66 
(m, 10H, ArH), 7.77 (s, 1H, arylidene-H), 12.84 (s, 1H, NH) ppm; 13C NMR (100 MHz, 
DMSO-d6) : 23.97, 27.08 (2CH3), 83.22, 123.80, 124.64, 127.80, 128.56, 129.37, 130.18, 
130.55, 132.67, 133.20, 143.43, 148.94, 158.57 (arylidene-C), 166.92, 168.31 (2C=O) ppm; 
HR-MS (ES-) calculated for C21H18N4O2S2 [M-H]






Yellow solid; yield: 75 %; mp 223-225 C; FT-IR (ATR, cm-1) max: 1024 (O-C), 1671 
(C=O), 3463 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.35 (s, 3H, CH3), 2.41 (s, 3H, CH3), 
3.84 (s, 3H, CH3); 7.11 – 7.63 (m, 9H, ArH), 7.72 (s, 1H, arylidene-H), 12.74 (s, 1H, NH) 
ppm; 13C NMR (100 MHz, DMSO-d6) : 24.04, 27.05 (2CH3), 55.56 (OCH3), 83.12, 114.98, 
120.45, 124.62, 125.62, 127.77, 128.54, 132.31, 132.76, 143.45, 148.97 (arylidene-C), 
158.63, 161.11, 167.04, 168.28 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(2-
nitrobenzylidene)thiazol-4(5H)-one (8c) 
Yellow solid; yield: 85 %; mp 188-190 C; FT-IR (ATR, cm-1) max: 1522 (N-O), 1723 
(C=O), 3580 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.18 (s, 3H, CH3), 2.37 (s, 3H, CH3), 
7.26 – 7.41 (m, 5H, ArH), 7.72 – 7.92 (m, 3H, ArH), 7.99 (s, 1H, arylidene-H), 8.21 – 8.23 
(m, 1H, ArH), 12.99 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 23.83, 27.05 
(2CH3), 83.17, 124.60, 125.51, 127.79, 128.40, 128.52, 128.94, 129.31, 129.58, 131.18, 
134.39, 147.89 (arylidene-C), 168.18 (2C=O) ppm; HRMS (ES-) calculated for 
C21H17N5O4S2 [M-H]
+: 466.0644; found: 466.0631. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(2,3-
dimethoxybenzylidene)thiazol-4(5H)-one (8d) 
Yellow solid; yield: 80 %; mp 240-241 C; FT-IR (ATR, cm-1) max: 1261 (O-C), 1723 
(C=O), 3431 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.29 (s, 3H, CH3), 2.39 (s, 3H, CH3), 
3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 7.11 – 7.44 (m, 8H, ArH), 7.87 (s, 1H, arylidene-H), 
12.89 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 23.92, 27.06 (2CH3), 55.97, 
61.15 (2OCH3), 83.18, 115.57, 120.03, 124.62, 124.73, 124.86, 126.83, 127.22, 127.78, 
128.54, 143.43, 148.26, 148.92, 152.82, 158.76, 166.93, 168.25 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(4-
bromobenzylidene)thiazol-4(5H)-one (8e) 
Dark yellow solid; yield: 87 %; mp 245-247 C; FT-IR (ATR, cm-1) max: 1711 (C=O), 3581 
(N-H); 1H NMR (400 MHz, DMSO-d6) : 2.33 (s, 3H, CH3), 2.40 (s, 3H, CH3), 7.28 – 7.61 
(m, 7H, ArH), 7.74 – 7.75 (m, 2H, ArH), 7.78 (s, 1H, arylidene-H), 12.89 (s, 1H, NH) ppm; 
13C NMR (100 MHz, DMSO-d6) : 24.05, 27.05 (2CH3), 83.22, 123.98, 124.62, 127.79, 
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128.53, 131.90, 132.35, 154.56, 165.73, 167.45 (2C=O) ppm; HR-MS (ES-) calculated for 
C21H17BrN4O2S2 [M-H]
+: 498.9898; found: 498.9888. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(4-
(benzyloxy)benzylidene)thiazol-4(5H)-one (8f) 
Yellow solid; yield: 79 %; mp 196-197 C; FT-IR (ATR, cm-1) max: 1249 (O-C), 1700 
(C=O), 3581 (N-H); 1H NMR (400 MHz, DMSO-d6) :
 2.34 (s, 3H, CH3), 2.40 (s, 3H, CH3), 
5.19 (s, 2H, CH2), 7.18 – 7.47 (m, 12H, ArH), 7.60 – 7.62 (m, 2H, ArH), 7.72 (s, 1H, 
arylidene-H), 12.75 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.02, 27.04 
(2CH3), 69.53 (CH2), 83.12, 115.74, 120.63, 124.62, 125.83, 127.80, 128.01, 128.48, 128.52, 
132.27, 132.68, 136.47, 143.44, 148.96, 158.64, 160.17, 167.02, 168.26 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(4-methyl -
benzylidene)thiazol-4(5H)-one (8g) 
Yellow solid; yield: 72 %; mp 246-248 C; FT-IR (ATR, cm-1) max: 1714 (C=O), 3386 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.33 (s, 3H, CH3), 2.36 (s, 3H, CH3), 2.40 (s, 3H, 
CH3), 7.27 – 7.45 (m, 7H, ArH), 7.53-7.55 (m, 2H, ArH), 7.72 (s, 1H, arylidene-H), 12.83 (s, 
1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 21.07, 23.93, 27.06 (3CH3), 83.13, 122.52, 
124.61, 127.76, 128.52, 129.96, 130.24, 130.41, 132.72, 140.88, 143.43, 148.97, 166.96, 
168.25 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(2-chloro -
benzylidene)thiazol-4(5H)-one (8h) 
Yellow crystals; yield: 88 %; mp 185-186 C; FT-IR (ATR, cm-1) max: 1716 (C=O), 3379 
(N-H); 1H NMR (400 MHz, DMSO-d6) : 2.27 (s, 3H, CH3), 2.39 (s, 3H, CH3), 7.27 – 7.53 
(m, 7H, ArH), 7.64 – 7.68 (m, 2H, ArH), 7.88 (s, 1H, arylidene-H), 12.97 (s, 1H, NH) ppm; 
13C NMR (100 MHz, DMSO-d6) : 23.93, 27.07 (2CH3), 83.27, 124.63, 127.45, 127.56, 
127.81, 128.03, 128.55, 129.16, 130.45, 131.16, 131.99, 134.49, 143.37, 148.85, 158.19, 
166.54, 168.29 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(4-nitro- 
benzylidene)thiazol-4(5H)-one (8i) 
Orange solid; yield: 78 %; mp 154-156 C; FT-IR (ATR, cm-1) max: 1514 (N-O), 1719 
(C=O), 3405 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.34 (s, 3H, CH3), 2.41 (s, 3H, CH3), 
7.28 – 7.46 (m, 5H, ArH), 7.85 (s, 1H, arylidene-H), 7.88-7.90 (m, 2H, ArH), 8.35-8.37 (m, 
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2H, ArH), 13.02 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.11, 27.07 (2CH3), 
83.33, 124.31, 124.62, 127.80, 128.13, 128.53, 129.80, 131.00, 139.52, 143.35, 147.45, 
148.79, 157.69, 166.58, 168.44 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(3-nitro- 
benzylidene)thiazol-4(5H)-one (8j) 
Light orange solid; yield: 72 %; mp 180-182 C; FT-IR (ATR, cm-1) max: 1526 (N-O), 1718 
(C=O), 3430 (N-H); 1H NMR (400 MHz, CDCl3) : 2.46 (s, 3H, CH3), 2.48 (s, 3H, CH3), 
7.27 – 7.51 (m, 5H, ArH), 7.66 – 7.70 (m, 1H, ArH), 7.83 – 7.85 (m, 2H, ArH), 8.28 – 8.31 
(m, 1H, ArH), 8.47 (s, 1H, arylidene-H) ppm, 13C NMR (100 MHz, CDCl3) : 24.34, 27.46 
(2CH3), 84.04, 123.71, 124.82, 125.12, 128.17, 128.56, 130.43, 131.29, 134.72, 136.41, 
148.74, 149.15, 154.78, 165.50 (2C=O) ppm.  
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(3,4-
dimethoxybenzylidene)thiazol-4(5H)-one (8k) 
Yellow solid; yield: 78 %; mp 186-187 C; FT-IR (ATR, cm-1) max: 1267 (O-C), 1692 
(C=O), 3430 (N-H); 1H NMR (400 MHz, CDCl3) : 2.38 (s, 3H, CH3), 2.47 (s, 3H, CH3), 
3.91 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 6.95 – 6.97 (m, 1H, ArH), 7.04 (s, 1H, ArH), 7.17-
7.19 (m, 1H, ArH), 7.27 – 7.37 (m, 3H, ArH), 7.49 – 7.51 (m, 2H, ArH), 7.79 (s, 1H, 
arylidene-H) ppm; 
13C NMR (100 MHz, CDCl3) : 24.31, 27.34 (2CH3), 55.86, 56.11 
(2OCH3), 83.65, 111.44, 112.31, 119.53, 125.13, 125.46, 125.90, 128.10, 128.50, 135.38, 
142.85, 149.45, 149.56, 151.65, 156.79, 166.54, 168.87 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(4-
(dimethylamino)benzylidene)thiazol-4(5H)-one (8l) 
Orange solid; yield: 71 %; mp 229-231 C; FT-IR (ATR, cm-1) max: 1713 (C=O), 3581 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.35 (s, 3H, CH3), 2.40 (s, 3H, CH3), 3.02 (s, 6H, N-
2CH3), 6.81 – 6.83 (m, 2H, ArH), 7.27 – 7.40 (m, 3H, ArH), 7.43 – 7.48 (m, 4H, ArH), 7.62 
(s, 1H, arylidene-H), 12.60 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.08, 
27.06 (2CH3), 82.93, 112.09, 115.70, 119.87, 124.62, 127.73, 128.53, 132.48, 133.96, 







Brown solid; yield: 73 %; mp 232-234 C; FT-IR (ATR, cm-1) max: 1715 (C=O), 3405 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.35 (s, 3H, CH3), 2.39 (s, 3H, CH3), 2.99 (s, 6H, N-
2CH3), 6.74 – 6.83 (m, 3H, ArH), 7.19 – 7.23 (m, 1H, ArH), 7.99 – 7.31 (m, 1H, ArH), 7.36 
– 7.42 (m, 4H, ArH), 7.45 (s, 1H, alkene-H), 7.53 (s, 1H, alkene-H), 7.55 (s, 1H, alkene-H), 
12.56 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 23.97, 26.75 (2CH3), 82.50, 




Yellow solid; yield: 76 %; mp 219-221 C; FT-IR (ATR, cm-1) max: 1701 (C=O), 3581 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.34 (s, 3H, CH3), 2.40 (s, 3H, CH3), 6.75 – 6.77 (m, 
1H, furyl-H), 7.11 – 7.12 (d, 1H, furyl-H), 7.27 – 7.44 (m, 5H, ArH),7.58 (s, 1H, arylidene-
H), 8.06 (d, 1H, furyl-H), 12.72 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.00, 
27.05 (2CH3), 83.08, 113.70, 118.98, 120.67, 124.61, 127.76, 128.54, 143.47, 147.68, 
149.04, 149.49, 159.65, 166.73, 168.25 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(3-chloro- 
benzylidene)thiazol-4(5H)-one (8o) 
Orange solid; yield: 85 %; mp 212-214 C; FT-IR (ATR, cm-1) max: 1726 (C=O), 3581 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.33 (s, 3H, CH3), 2.40 (s, 3H, CH3), 7.27 – 7.45 (m, 
5H, ArH), 7.56 – 7.63 (m, 3H, ArH), 7.71 (s, 1H, ArH), 7.75 (s, 1H, arylidene-H), 12.95 (s, 
1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 23.96, 27.06 (2CH3), 83.21, 124.63, 
125.78, 127.81, 128.55, 128.70, 129.44, 130.03, 130.91, 131.18, 133.94, 135.41, 143.39, 
148.98, 166.73, 168.21 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(2-fluoro- 
benzylidene)thiazol-4(5H)-one (8p) 
Yellow crystals; yield: 81 %; mp 185-186 C; FT-IR (ATR, cm-1) max: 1697 (C=O), 3491 
(N-H); 1H NMR (400 MHz, DMSO-d6) : 2.30 (s, 3H, CH3), 2.40 (s, 3H, CH3), 7.27 – 7.31 
(m, 1H, ArH), 7.36 – 7.45 (m, 6H, ArH), 7.54 – 7.64 (m, 2H, ArH), 7.75 (s, 1H, arylidene-
H), 12.93 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 23.62, 26.75 (2CH3), 82.93, 
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116.13, 120.80, 123.24, 124.31, 125.07, 126.17, 127.48, 128.22, 128.86, 132.52, 132.61, 
143.07, 148.54, 157.81, 158.94, 161.45, 166.31, 167.97 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(thiophen -2-
ylmethylene)thiazol-4(5H)-one (8q) 
Yellow solid; yield: 89 %; mp 222-225 C; FT-IR (ATR, cm-1) max: 1701 C=O, 3489 NH;
 1H 
NMR (400 MHz, DMSO-d6) : 2.38 (s, 3H, CH3), 2.41 (s, 3H, CH3), 7.28 – 7.46 (m, 5H, 
ArH, 1H, thienyl-H), 7.72 – 7.73 (d, 1H, thienyl-H), 8.05 (m, 1H, thienyl-H), 8.06 (s, 1H, 
arylidene-H), 12.79 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.07, 27.07 
(2CH3), 83.04, 121.01, 124.62, 125.99, 127.79, 128.56, 129.02, 133.64, 135.33, 137.37, 
143.46, 149.09, 157.94, 166.70, 168.23 (2C=O) ppm.  
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(pyridin-2-
ylmethylene)thiazol-4(5H)-one (8r) 
Orange solid; yield: 68 %; mp 213-215 C; FT-IR (ATR, cm-1) max: 1716 (C=O), 3406 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.33 (s, 3H, CH3), 2.41 (s, 3H, CH3), 7.28 – 7.45 (m, 
5H, ArH), 7.58 – 7.59 (m, 2H, ArH); 7.72 (s, 1H, arylidene-H), 8.74 – 8.75 (m, 2H, ArH) 
12.94 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.04, 27.07 (2CH3), 83.38, 
123.58, 124.63, 127.82, 128.56, 129.03, 129.33, 140.54, 143.36, 148.79, 150.39, 157.74, 
166.56, 168.39 (2C=O) ppm.  
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-(3-
methoxybenzylidene)thiazol-4(5H)-one (8s) 
Yellow solid; yield: 71 %; mp 180-182 C; FT-IR (ATR, cm-1) max: 1229 (O-C), 1721 
(C=O), 3430 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.31 (s, 3H, CH3), 2.40 (s, 3H, CH3), 
3.80 (s, 3H, OCH3), 7.06 – 7.08 (m, 1H, ArH), 7.20 – 7.31 (m, 3H, ArH), 7.36 – 7.46 (m, 5H, 
ArH), 7.74 (s, 1H, arylidene-H), 12.84 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 
23.95, 27.08 (2CH3), 55.25 (OCH3), 83.07, 114.64, 116.84, 122.74, 123.99, 124.62, 127.79, 




Yellow solid; yield: 89 %; mp 203-206 C; FT-IR (ATR, cm-1) max: 1715 (C=O), 3392 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.33 (s, 3H, CH3); 2.40 (s, 3H, CH3); 7.28 – 7.45 (m, 
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5H, ArH); 7.60 – 7.67 (m, 4H, ArH); 7.75 (s, 1H, arylidene-H), 12.87 (s, 1H, NH) ppm; 13C 
NMR (100 MHz, DMSO-d6) : 24.05, 27.07 (2CH3), 83.24, 124.56, 124.64, 127.81, 128.55, 




Orange solid; yield: 86 %; mp 232-234 C; FT-IR (ATR, cm-1) max: 1241 (O-C), 1701 
(C=O), 3581 (N-H); 1H NMR (400 MHz, DMSO-d6) : 2.35 (s, 3H, CH3), 2.39 (s, 3H, CH3), 
3.80 (s, 3H, OCH3), 6.87 (m, 1H, alkene-H), 6.97– 6.99 (m, 2H, ArH), 7.24 – 7.31 (m, 2H, 
ArH), 7.36 – 7.46 (m, 5H, ArH), 7.63 (d, 1H, alkene-H), 7.65 (d, 1H, alkene-H), 12.61 (s, 1H, 
NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.31, 27.08 (2CH3), 55.35 (OCH3), 82.92, 
114.49, 120.76, 122.84, 124.61, 127.74, 128.34, 128.53, 129.75, 133.61, 143.52, 144.12, 
149.01, 158.30, 160.78, 166.47, 168.43 (2C=O) ppm. 
(Z)-2-((4-acetyl-5-methyl-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)amino)-5-((E)-3-
phenylallylidene)thiazol-4(5H)-one (8v) 
Orange solid; yield: 86 %; mp 229-231 C; FT-IR (ATR, cm-1) max: 1717 (C=O), 3581 (N-
H); 1H NMR (400 MHz, DMSO-d6) : 2.35 (s, 3H, CH3), 2.39 (s, 3H, CH3), 7.03 – 7.09 (m, 
1H, alkene-H), 7.26 – 7.40 (m, 5H, ArH), 7.42 – 7.48 (m, 5H, ArH), 7.67 (d, 1H, alkene-H), 
7.69 (d, 1H, alkene-H), 12.69 (s, 1H, NH) ppm; 13C NMR (100 MHz, DMSO-d6) : 24.3, 
27.0 (2CH3), 82.99, 123.08, 124.60, 127.75, 127.91, 128.53, 128.95, 129.81, 132.90, 135.58, 
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4.1. In vitro evaluation against kinase targets (CDK and Abl) 
All the synthesized final compounds (8a-v) were evaluated for in vitro CDK2/ cyclin E and 
Abelson murine leukaemia (Abl) kinase inhibitory activity as well as anti-proliferative 
activity against K-562 (chronic myelogeneous leukaemia), and MCF-7 cell lines. The data 
obtained are shown in Table 4.  
Table 4: Kinase (CDK2/E and Abl) inhibition and anti-proliferative activity data of the final  
               compounds (8a-v). 
aIC50 values were determined in triplicate in the range of 0.05 to 100 µM. IC50 value indicates concentration 
(µM) that inhibits activity of tested enzyme to 50% or for cytotoxic assays, concentration (µM) that reduces 
50% of cells during a three-day cultivation.  
 
Most of the synthesized compounds displayed good inhibitory effect against CDK2 at 
the micromolar level. These derivatives could be ideal starting point molecules toward the 
development of novel anticancer agents. As the total number of evaluated compounds is quite 
appreciable, a meaningful structure-activity relationship (SAR) was established and potent 
active members in the series were identified. A positive correlation was observed between the 
effect of diversified substituents on aromatic ring/bioisosteric replacement and inhibitory 
Compounds IC50 (µM)
a  Cytotoxicity in cancer cell lines GI50 (µM)a 
CDK2/E Abl K-562 MCF-7 
8a 5.1 >25 >6.25 >6.25 
8b 3.2 >25 >6.25 >6.25 
8c 6.0 >25 >6.25 >6.25 
8d 3.8 >25 >6.25 >6.25 
8e 6.3 >25 >6.25 >6.25 
8f 4.4 >25 >6.25 >6.25 
8g 5.8 >25 >6.25 >6.25 
8h 3.1 >25 >6.25 >6.25 
8i 3.2 >25 >6.25 >6.25 
8j 10.4 >12.5 >6.25 >6.25 
8k 3.6 >12.5 >6.25 >6.25 
8l 4.6 >25 >6.25 >6.25 
8m 8.6 >25 >6.25 >6.25 
8n 17.2 >25 >6.25 >6.25 
8o 3.9 >25 >6.25 >6.25 
8p 5.8 >25 >6.25 >6.25 
8q 4.1 >25 >6.25 >6.25 
8r 9.7 >25 >6.25 >6.25 
8s 3.3 >25 >6.25 >6.25 
8t 3.4 >25 >6.25 >6.25 
8u 3.5 >25 >6.25 >6.25 
8v 4.5 >25 >6.25 >6.25 
Roscovitine 0.1 >100 42 11 
Imatinib >100 0.2 0.5 >10 
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potential of CDK2/E. Of the 22 evaluated derivatives, 10 compounds showed potent CDK2/E 
inhibition with IC50 ranging from 3.1 to 4.1 µM. Compounds bearing electron-withdrawing 
halogens (Cl) and weak electron donating groups (OCH3) bound on their aromatic ring 
showed more potency. Among the halogenated derivatives, chlorine in the ortho position of 
the aromatic ring (8h) demonstrated higher potency (IC50 = 3.1 µM) followed the same 
chlorine on the para- (8t) and meta (8o) position resulted IC50 values 3.4 µM and 3.9 µM, 
respectively. 
Substitution using other halogens such as fluorine or bromine showed a moderate 
inhibition (IC50) at 5.8 µM (8p) and 6.3 µM (8e), respectively. In comparison with chlorine, 
the methoxy substituent also equally contributed to the inhibitory potential of the final 
compounds. Remarkably, compound 8b and 8s bearing OCH3 at para and meta position of 
the aromatic ring showed higher inhibition at 3.2 and 3.3 µM, respectively. Elongation of the 
linker by two carbon distance (8u) did not exhibit a substantial improvement in the activity 
against CDK2 (IC50 = 3.5 µM) even when the methoxy substituent was retained at the para 
position. Similarly, dimethoxy substitution on different positions of the ring (8k and 8d) did 
not show any significance effect. The introduction of an additional aromatic ring (8f), and an 
extended conjugation with two carbon distance on the thiazolone moiety (8v) resulted in 
moderate inhibition of CDK2 (IC50 = 4.5 µM). However, for unsubstituted derivative 8a there 
was a low potency (IC50 = 5.1 µM). Compounds substituted with weak electron donating 
groups (CH3 and N-(CH3)2) on para position of the aromatic ring (8g and 8l) displayed 
moderate inhibition. Exocyclic conjugation with additional two carbons (8l) resulted in the 
formation of 8m which demonstrated lower inhibition (IC50 = 8.6 µM).  
As shown in Table 4, 8i the compound bearing a nitro (strong electron withdrawing) 
group on para position of the aromatic ring exhibited potent inhibitory effect with an 
impressive IC50 value of 3.2 µM. Surprisingly, the nitro substituent at meta position of the 
aromatic ring (8j) showed lower CDK2 inhibition (IC50 = 10.4 µM). Bioisosteric replacement 
of phenyl ring (8a) with thiophene (8q) retained its inhibitory potential with an IC50 of 4.1 
µM. Whereas, replacing a phenyl group with other heterocycles such as 2-pyridyl (8r) and 
furan (8n) resulted in lower activity compared to other synthesized compounds. Conversely, 
when comparing the inhibitory profiles of the synthesized compounds 8a-v against the 




4.1.1. SAR Analysis 
The SAR of the synthesized compounds 8a-v and their in vitro CDK2/ cyclin E profiles are 
presented in Fig. 27. 
 
Figure 27: SAR of 8a-v against CDK2. 
Surprisingly, a couple of compounds (8j and 8k) exhibited moderate inhibition (IC50 
>12.5 µM) against the Abl kinase compared with the standard imatinib (IC50 = 0.2 µM). 
However, these compounds can be considered as potent compounds when compared with 
standard roscovitine (IC50 >100 µM). All other derivatives in this series exhibited poor 
inhibition of Abl kinase (IC50 >25 µM). Interestingly, all the synthesized compounds 8a-v 
exhibited good anti-proliferative activity (IC50 >6.25 µM) against both the K-562 and MCF-7 
cell lines. When compared to the standard drugs (roscovitine and imatinib), the compounds 
8a-v showed great inhibitory profiles. When they were further evaluated against MCF-7 cell 
line they showed an impressive inhibitory effect suggesting that they can be potential anti-
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breast cancer hit compounds. It was also observed that the inhibitory profiles of the 8a-v were 
higher (IC50 >6.25 µM) against K-562 when compared to the standard roscovitine (IC50 = 42 
µM).  
4.2. Experimental (in vitro) 
4.2.1. In vitro evaluation against CDK2 and Abl kinase  
Kinase assays were performed using a 96-well plate setup with recombinant CDK-cyclin 
complexes generated on the Cyclacel. CDK2 and Abl assays were performed using an assay 
buffer consisting of 25 mM b-glycerolphosphate, 20 mM MOPS, 5 mM EGTA, 1 mM DTT, 
and 1 mM NaVO3 at pH 7.4. To this buffer, 2–4 μg of active enzyme was added with an 
appropriate substrate (purified histone H1 for CDK2/cyclin, Abl). Ice was used to stop the 
reaction, then 50 mg avidin was added to each well and incubated for 10 min, the solution 
was filtered through p81 or GF/C filter plates (WhatmanPolyfiltronics). Then the plate was 
washed three times with 75 mM aqueous orthophosphoric acid, and dried. The scintillant 
(Microscint 40) was then added, and incorporated radioactivity measured with a scintillation 
counter (TopCount; Packard Instruments). CDK2 and Abelson murine leukemia viral 
oncogene homolog-1 (Abl-1) were assayed using commercial assay kits (AmershamBiotrak 
CDK2 and Abl1 assay kits). Data was analyzed using curve-fitting software (GraphPad Prism 
version 3.00 for Windows) to determine IC50 values (concentrations inhibiting kinase activity 
by 50%) [1]. 
4.2.2. Anti-proliferative activity against K-562 and MCF-7 cell lines 
The tumour cells (purchased from the American Type Culture Collection and the German 
Collection of Microorganisms and Cell Cultures) were grown in DMEM medium (Gibco 
BRL) supplemented with 10% (v/v) fetal bovine serum and L-glutamine (0.3 g/L). The 
tumour cells were then maintained at 37°C in a humidified atmosphere with 5% CO2. For 
anticancer cytotoxicity estimations, 104 cells were seeded into each well of a 96-well plate, 
and they were allowed to stabilize for atleast 4 h. Test inhibitors were then added at different 
concentrations (ranging from 0.1 to 100 μM) in triplicate. Three days after addition of the 
inhibitors, calcein AM solution (Molecular Probes) was added. An hour later, fluorescence of 
cells was quantified using a Fluoroskan Ascent (Labsystems) reader. Cytotoxic effective 
concentrations were calculated and expressed as IC50 values deduced from the dose-response 
curves. The p53 status of the cell lines was considered to be wild-type or mutant (including 
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deletions) according to the literature [2, 3]. Roscovitine and imatinib were used as reference 
drugs. 
4.3. In silico evaluation against CDK 
To get an insight into the binding motif of the active compounds with the CDK2 protein, a 
molecular docking was performed. Glide program of Schrodinger-Maestro 11.2 was 
employed for validation of the docking protocols and to reproduce the orientation of R-
roscovitine reported in the PDB structure (ID: 2A4L). The pose of R-roscovitine obtained 
from the docking results revealed similar molecular interactions as reported in the literature 
[3]. The docked complex presented characteristic hydrogen bonding (H-bond) interactions 
with crucial active-site residues. A strong H-bond (1.91 Å) was observed between 
benzylamino NH- of R-roscovitine with a hinge residue (Leu83), whereas a weak H-bond 
(2.39 Å) was demonstrated by C=O (R-roscovitine) with a ring N of the same residue 
(Leu83). Similarly, Asp86 interacted with OH group of R-roscovitine via a strong H-bond 
(1.67 Å), whereas Lys89 exhibited π–cation interaction with a phenyl ring of the ligand. Fig. 
28 represents the reproduced 3D molecular interactions of the docked pose. 
 
 
Figure 28: Reported pose (wire-frame model) and docked pose (thick tube model; green  
       coloured) into the active-site showing similar interactions (docking validation). 
The docking of the synthesized compounds with CDK2 protein revealed that they 
docked well into the binding-site and displayed favourable interactions with the crucial amino 
acid residues. The docked pose of the active compound 8u demonstrated a strong H-bond 
between the carbonyl oxygen (C=O) of thiazolone motif and –HN- of Asn132 at a distance of 
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2.08 Å. The thiadiazole moiety settled well in the binding-site surrounded by the residues of 
Asp127, Gly131, Glu162, Val164, and Thr165 showing hydrophobic interactions. The 
extended conjugation from the thiazolone moiety guided the phenolic ring to orient towards 
aromatic amino acid residues Phe80, Phe82, and His84. There were no significant H-bond 
interactions identified with the other H-bond donors, for example, the phenolic hydroxyl and 
secondary amino groups.  
In the case of the moderately active compound 8m, the C=O of thiazolone displayed 
two H-bond interactions with Asn132 (1.96 Å) and Lys129 (2.53 Å), respectively. The 
hydrophobic interactions were observed for the thiadiazole moiety with the residues of 
Thr14, Thr158, Glu162, Val163 and Val164. The extended conjugation in the thiazolone 
directed the N,N-dimethylamino to orient towards aromatic amino acid residues Phe80, 
Phe82, and His84. The compound 8n (least active) showed an orientation of docked pose that 
is different from 8u (active) and 8m (moderately active). The C=O of thiazolone motif and 
H-bond donating secondary amine (NH-) of 8n displayed H-bond interactions toward Lys33 
(NH-) and Gln131 (C=O), respectively. The furyl ring exhibited a π–π interaction with an 
aromatic residue Phe80. From the docking results, it was deduced that the molecular 
interaction of the synthesized compounds with the basic residue Asn132 is very crucial in 
influencing the in vivo CDK2 inhibition of the compounds. Fig. 29 presents the different 









Figure 29: Molecular interactions of a) active compound 8u b) moderately active compound  
       8m c) less active compound 8n into the binding site of CDK2/cyclin E protein.  
       Nonpolar hydrogens were hidden for clarity and yellow dashed line indicate H  
       bond. 
 
4.4. Experimental (in silico) 
4.4.1.  Molecular docking simulation 
Molecular docking was performed using Glide software package [4] implemented in 
Schrodinger Suite (2017-2) (Schrödinger, Inc., USA) running on Intel CORE i7 based 
hpZ230 workstation with the Microsoft Windows 10 OS. In this protocol, the protein 




4.4.2.  Protein preparation 
The X-ray solved protein crystal structure of CDK2 bound with R-roscovitine was retrieved 
from PDB bearing ID 2A4L [5, 6]. The protein was automatically prepared by Protein 
Preparation Wizard of Glide via the Optimized Potentials for Liquid Simulations 3 (OPLS3) 
forcefield. During the pre-processing stage, crystallographic water molecules were removed 
and missing hydrogen atoms were added to the protein structure corresponding to pH 7.0. 
The protein’s metal ions and cofactors were also viewed and removed from the protein 
structure. This tool neutralized the side chains that were far from the binding cavity and that 
did not participate in salt bridges. The pre-processed protein structure was initially refined by 
optimizing the sample-water orientation followed by restrained minimization of co-
crystallized complex using OPLS3. This process reoriented the side chain hydroxyl groups 
and alleviated potential steric clashes. Thus, the complex obtained was minimized until it 
reached the convergent of heavy atom to RMSD 0.3 Å and finally taken in .mae format. 
4.4.3.  Grid file generation 
Receptor-grid generation protocol of Maestro 11.2 was used to define the binding-site of the 
protein for docking simulation. This was done by excluding any co-crystallized metals, co-
factors, water molecules that might have crystallized during experimental crystallization of 
the CDK-2 protein. A grid box was generated around the centroid of the cognate ligand (R-
roscovitine) specifying the size for the docking ligands (20 Å) with default settings.  
4.4.4.  Ligand preparation 
Structures of the synthesized ligands and standard R-roscovitine were sketched using built 
panel of Maestro and taken in .mae format. LigPrep is a utility of Schrodinger software suit 
that combines tools for generating 3D structures from 1D (Smiles) and 2D (SDF) 
representation, searching for tautomers, steric isomers and perform a geometry minimization 
of the ligands. By employing Ligprep protocol, all the ligands were prepared using OPLS3 
with default settings and the output file was automatically saved in .maegz format. 
4.4.5.  Docking simulation 
For the precision and accuracy of the docking protocols, the co-crystallized ligand was 
extracted from the crystal structure and re-docked using Glide docking algorithm 
(Schrodinger Inc) in its extra precision (XP) mode with default settings without applying any 
constraints. A good agreement of the obtained docked pose of R-roscovitine with cognate 
ligand indicated the reliability of the selected docking parameters. Hence, by specifying the 
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ligands against the receptor grid, molecular docking was performed using default settings in 
Glide XP mode. 
4.4.6.  Binding mode analysis 
The protein-ligand complexes were analysed to investigate various types of interactions using 
the XP visualizer protocol. For the best-scored ligands, the 2D and 3D plots of molecular 
ligand-receptor interactions were analysed for H-bond, halogen bond, salt bridges, π-π 
stacking, and π-cation interactions. 
 
4.5. References  
[1] V. Kryštof, I. McNae, M. Walkinshaw, P. Fischer, P. Müller, B. Vojtěšek, M. Orsag, L.  
Havlíček, M. Strnad, Antiproliferative activity of olomoucine II, a novel 2, 6, 9- 
trisubstituted purine cyclin-dependent kinase inhibitor, Cellular and molecular life  
sciences, 62 (2005) 1763. 
[2] P.M. O'Connor, J. Jackman, I. Bae, T.G. Myers, S. Fan, M. Mutoh, D.A. Scudiero, A.  
Monks, E.A. Sausville, J.N. Weinstein, Characterization of the p53 tumor suppressor  
pathway in cell lines of the National Cancer Institute anticancer drug screen and  
correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer  
research, 57 (1997) 4285. 
[3] M. Olivier, R. Eeles, M. Hollstein, M.A. Khan, C.C. Harris, P. Hainaut, The IARC TP53  
database: new online mutation analysis and recommendations to users, Human  
mutation, 19 (2002) 607. 
[4] R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren,  
P.C. Sanschagrin, D.T. Mainz, Extra precision glide: Docking and scoring 
incorporating a model of hydrophobic enclosure for protein− ligand complexes, 
Journal of medicinal chemistry, 49 (2006) 6177. 
[5] L. Prabhu, L. Chen, H. Wei, O. Demir, A. Safa, L.-F. Zeng, R. Amaro, B.H. O'Neil, Z.-Y.  
Zhang, T. Lu, Development of AlphaLISA high throughput technique to screen for  
small molecule inhibitors targeting protein arginine methyltransferases, Molecular  
biosystems, 13 (2017) 2509. 
[6] W.F. Azevedo, S. Leclerc, L. Meijer, L. Havlicek, M. Strnad, S.H. Kim, Inhibition of  













5.1. In vitro evaluation against KSP 
All the synthesized final compounds 8a-v were evaluated for their potential inhibition of MT-
stimulated KSP ATPase activity using established in vitro assay protocols [1, 2]. The data 
obtained for 8a-v and K-858 (reference standard) are shown in Table 5. 
 
Table 5: Inhibition of the MT-stimulated ATPase activity of KSP by the final compounds  
               8a-v and K-858.  
 






































































































*: Maximum inhibition attained in percentage. 
**: IC50 values calculated by Kaleidagraph. 
^: IC50 values extracted manually.  
NT: not tested. 
 
Most of the compounds displayed good to moderate inhibition (micro molar ranges) 
of the MT-stimulated KSP ATPase activity when compared to the standard K-858. As the 
total number of evaluated compounds is quite appreciable, a meaningful SAR was 
established. A positive correlation was recognized between the presence of diversified 
substituents on the aromatic ring of the thiazolone and their inhibitory potential on KSP 
ATPase activity.  
Ten of the tested compounds showed considerable inhibition of the MT-stimulated 
KSP ATPase activity with IC50 values ranging from 13.2 to 62.1 µM. Compounds bearing 
electron-withdrawing groups such as halogen (Cl), nitro (NO2), and weak electron donating 
groups (OCH3, OBz) on the aromatic ring demonstrated higher inhibition activity. Within the 
halogenated derivatives, chlorine at the 2nd position of the aromatic ring (8h) showed the 
most significant inhibition with an IC50 of 13.2 µM. However, moderate (IC50 = 47.8 µM), 
and poor (IC50 = 106.2 µM) inhibitions were observed when the chlorine was substituted at 
the 3rd (8o) and 4th (8t) positions, respectively. The 4-bromo substituted analogue 8e 
displayed a moderate (39.2 µM) inhibition, while a three-fold decrease (132.9 µM) in the 
activity was observed for fluorine at the 2nd position (8p). The benzyloxy substituted 
compound 8f also displayed a significantly higher inhibition of the MT-stimulated KSP 
ATPase activity with an IC50 of 17.2 µM.  
Compared to other electron-withdrawing substituents (e.g. chlorine), nitro-bearing 
compounds also showed relatively good inhibitory potential. Remarkably, compounds 
bearing the nitro group at 4th (8i) and 3rd position (8j) of the phenyl ring exhibited almost the 
same inhibition (20.2 µM and 27.5 µM, respectively). This observation indicated that there is 
no significant difference between these two substitutions in terms of enzyme inhibition.  
K-858 
 




Methoxy substitution (8b) gave a moderate inhibition with IC50 of 42.7 µM, while 
dimethoxy substitution (8d) (IC50 = 71.9 µM) did not improve the activity, rather a one-fold 
decrease was observed. Compounds that were unsubstituted (8a) or 4-methyl substituted (8g) 
presented similar IC50 values (~ 62 µM). Extending the exocyclic unsaturation of 8a yielded 
8v which resulted in a decrease in potency by four-fold (IC50 = 247.6 µM). The latter 
revealed that extending the conjugation does not substantially increase the potency of a 
compound. 
Presence of two methoxy groups at the 3rd and 4th positions of phenyl ring in 8k 
displayed a weaker inhibitory effect (IC50 = 111.9 µM). An extended unsaturation on 
thiazolone with a methoxy substituent (8u) at position 4 showed weaker inhibition. The N,N-
dimethylamino substituent on the phenyl in 8l demonstrated poor inhibition (IC50 = 252.2 
µM), whereas, exocyclic conjugation with additional two carbons (8m) resulted in one-fold 
increase in the potency (IC50 = 128.7 µM) when compared to 8l. Bioisosteric replacement of 
phenyl ring of 8a with pyridine (8r) or thiophene (8q) resulted in reduced inhibition with IC50 
values 120 µM and 133.5 µM, respectively. Bioisosteric replacement using furan (8n) 
showed very poor or no inhibition (IC50 = 330.6 µM) of MT-stimulated KSP ATPase activity.  
5.1.1. SAR Analysis 
A brief SAR analysis revealed that the chloro substituent at 2nd position of the phenyl ring 
(8h) of the thiazolone motif exhibited higher potency followed by a highly electron-
withdrawing nitro group at the 4th position (8i) (Fig. 30). The presence of an electron 
donating functionalities on the aromatic ring yielded relatively moderate potency. In addition, 
the unsubstituted compounds and analogues bearing bioisosterically-replaced moieties 








5.2.  Experimental (in vitro) 
5.2.1. Inhibition of the MT-stimulated KSP ATPase activity  
The experiments were performed at 25 °C using a 96-well Sunrise photometer (Tecan, 
Mannesdorf, Switzerland) with a final volume of 100 μL per well. The MT-stimulated KSP 
ATPase rates were measured using the pyruvate kinase/lactate dehydrogenase linked assay in 
the buffer A25 [25 mmol/L potassium ACES (pH 6.9), 2 mmol/L magnesium acetate, 2 
mmol/L potassium EGTA, 0.1 mmol/L potassium EDTA, 1 mmol/L β-mercaptoethanol]. The 
amounts of KSP was optimized at 5 nM for the assay. The IC50 values for the inhibition of 
the MT-stimulated ATPase activities of KSP were measured between 1 and 200 μM for 
positive control (K-858). The ATP concentration was fixed at 1 mM, whilst the MT 
concentration was kept at 1 μM. The data was analyzed using Kaleidagraph 3.0 (Synergy 
Software Reading, PA) and Microsoft Excel to obtain IC50 values [1, 2].  
 
5.3. In silico evaluation of TDT against KSP 
5.3.1. Molecular docking simulation 
Molecular docking simulations were performed in order to gain more insight into the binding 
mode of the synthesized compounds 8a-v in the active-site of KSP and to further support the 
SAR study. This molecular docking was performed using X-ray crystal structure of KSP 
complexed with a thiophene containing inhibitor K-03 [PDB ID: 2UYM] [3]. Prior to the 
docking of the synthesized ligands, the protocol was validated by docking a cognate ligand 
(K03) into the pre-defined binding site of KSP using Glide module [4] of Schrodinger-
Maestro 11.2 [5] with default settings. The docked pose of K-03 revealed a similar type of 
binding orientation and molecular interactions with crucial amino acid residues of KSP as 
that of the cognate ligand in PDB structure. Apart from exhibiting essential molecular 
interactions, the secondary amino NH of K03 showed a weak hydrogen bonding (2.56 Å) 




Figure 31: The docked pose of the ligand (pink coloured ball-stick model) with the pose of  
       the native K-03 extracted from PDB (yellow coloured ball-stick model) in the  
       active-site residues of KSP (wire-frame). Nonpolar hydrogens were hidden for  
       clarity and the yellow dashed line indicates a hydrogen bond. 
 
The most active compound 8h docked well into the active site of KSP (PDB ID: 
2UYM) and exhibited molecular interactions with crucial amino acid residues (Fig. 32a). The 
secondary amino NH- of 8h demonstrated a strong H-bonding (1.75 Å) interaction with -
O=C of Glu116. Furthermore, 2-chloro phenyl ring of 8h exhibited a remarkable π-cation 
interaction with the basic residue Arg119 and showed hydrophobic interactions with the 
residues Trp127, Tyr211, and Leu132. The phenyl ring at the chiral center of thiadiazole core 
moiety settled well in the binding pocket surrounded by the residues of Arg221, Glu162, 
Tyr231, and Ser237. As expected, there is no hydrogen bonding interaction was observed for 
the carbonyl oxygens of 8h towards any of the active-site residues of KSP (Fig. 32a).  
The docked pose of weakly active compound 8u disclosed a weak H-bonding 
interaction between NH- of the ligand and –O=C of Gly117 at a distance of 1.94 Å (Fig. 
32b). Also, a π-cation interaction between the methoxy phenyl ring of 8u and the basic 
residue Arg221 was observed in the docked pose. The phenyl ring on the chiral carbon of 8u 
was encompassed by the active-site residues of Tyr211, Leu214, and Phe239. The methoxy 
phenyl substitution of 8u was buried in the cavity formed by amino acid residues such as 







Figure 32: 3D-molecular interactions of a) 8h (more active); b) 8u (weakly active) in the  
                   binding site of KSP. Nonpolar hydrogens were hidden for clarity and yellow  
                   dashed line indicates H-bond, whereas green coloured dashed lines indicate π- 
                   cation interactions. 
 
From the docking simulations, it was deduced that H-bonding interaction of 
secondary amino NH- with –O=C of Glu116 is crucial for the enzyme inhibition which had a 
positive impact on the in vitro assay outcome, accordingly. Highly active compounds such as 
8h could retain this crucial H-bond interaction with the Glu116, whereas the less active 
compound (8u) could not. It is also interesting to note that a flipped orientation of the side 
chain phenyl ring of 8u was observed due to the presence of an extended conjugation from 
thiazolone moiety (Fig. 32b). This flipping pattern in 8u guided the orientation of the 
methoxy phenyl ring more towards the acidic amino acid residues displaying a π-cation 
interaction with Arg221 instead of Arg119 which was observed for the most active 
compound 8h. Hence, deviation from these essential molecular interactions with specific 





5.3.2.  In silico prediction of drug likeliness and pharmacokinetic (ADME) 
parameters  
In order to recognize the synthesized compounds 8a-v to be drug-like molecules, we have 
evaluated them against Lipinski's rule of five in which molecular properties are correlated 
with the oral bioavailability of a drug/drug-like compound. The QikProp of Schrodinger 
Maestro-11.2 [6] was used to determine the drug likeliness (Lipinski's rule of rive) and in 
silico ADME (absorption, distribution, metabolism, and excretion) parameters. The results 
(Table 6) demonstrated that all the synthesized compounds complied with the rule except 8e, 
8f and 8m. These compounds did not comply with a couple of the properties (molecular 
weight and QPlogP O/W) as they violated 1 or 2 out of 5 properties (Lipinski's rule of five). 
In addition, numerous drug candidates that failed during clinical trials were because of issues 
related to the ADME pharmacokinetic properties being violated. Human intestinal absorption 
(HIA) and Caco-2 permeability (QPPCaco) parameters are good indicators of drug 
absorbance in the intestine and Caco-2 monolayer penetration, respectively. HIA data is a 
sum of bioavailability and absorption obtained from the ratio of excretion or cumulative 
excretion in urine, bile, and feces [7]. Similarly, QPPCaco parameter is a key feature that 
regulates the drug metabolism and its access through the biological membranes [8]. The 
predicted percentages of human oral absorption for 8a-v were 80.84% to 100% in all cases 
and permeability values (QPPCaco) ranged from 92.946 to 968.211 clearly indicating that all 
the synthesized compounds theoretically have good oral absorption.  
The partition coefficient (QPlogPo/w) and water solubility (QPlogS) are thecrucial 
factors with regards to the absorption and distribution of the drugs in a human body. For the 
synthesized molecules 8a-v, QPlogPo/w, and QPlogS values ranged from 3.188 to 5.759 and 
-8.093 to -4.981, respectively. Furthermore, we predicted the number of violations of 
Jorgensen's rule of three with the recommended parameters (QPlogS > -5.7, QPPCaco > 22 
nm/s, primary metabolites < 7) [9]. Except 8n and 8r, most of the compounds deviated by 
one parameter out of three. Thus, the QikProp predicted the physico-chemically significant 
descriptors and pharmaceutically relevant properties, and all established that compounds 8a-v 





Table 6: The drug likeliness and in silico ADME properties of synthesized compounds 8a-v by QikProp. 
 
 










Violation of  
Lipinski's 
rule 




of rule of 
three 
8a 422.519 3.891 1 7.50 0 -5.864 -6.623 916.992 992.873 0.342 100 1 
8b 452.545 3.927 1 8.25 0 -5.978 -6.465 905.090 981.113 0.322 100 1 
8c 467.516 3.270 1 8.50 0 -5.937 -6.501 125.105 115.654 0.298 83.632 1 
8d 482.571 4.011 1 9.00 0 -5.948 -6.255 968.211 1032.439 0.308 100 1 
8e 501.415 4.459 1 7.50 1 -6.720 -6.560 905.090 2602.580 0.480 93.013 1 
8f 528.643 5.759 1 8.25 2 -8.093 -8.118 914.792 1000.235 0.901 87.749 1 
8g 436.546 4.191 1 7.50 0 -6.425 -6.525 905.090 981.105 0.495 100 1 
8h 456.964 4.319 1 7.50 0 -6.749 -6.518 905.833 2142.073 0.442 100 1 
8i 467.516 3.188 1 8.50 0 -6.553 -6.591 92.946 83.865 0.305 80.838 1 
8j 467.516 3.195 1 8.50 0 -6.075 -6.575 97.448 86.006 0.305 81.247 1 
8k 482.571 3.908 1 9.00 0 -5.944 -6.283 916.992 921.033 0.282 100 1 
8l 465.587 4.223 1 8.50 0 -6.650 -6.701 770.211 592.801 0.503 100 1 
8m 491.625 5.134 1 8.50 1 -7.587 -7.188 926.505 1102.894 0.705 100 1 
8n 412.480 3.200 1 8.00 0 -4.981 -6.112 926.505 1027.827 0.062 100 0 




aPredicted octanol/water partition co-efficient log p (acceptable range from -2.0 to 6.5). 
bPredicted aqueous solubility in mol/L (acceptable range: -6.5 to 0.5). 
cPredicted IC50 value for blockage of HERG K+ channels (concern below -5.0). 
dPredicted Caco-2 cell permeability in nm/s (acceptable range: <25 is poor and >500 is great). 
ePredicted apparent MDCK cell permeability in nm/s (acceptable range: <25 is poor and >500 is great). 
fPrediction of binding to human serum albumin (acceptable range: -1.5 to 1.5). 
gPercentage of human oral absorption (<25% is poor and >80% is high)
8p 440.509 4.091 1 7.50 0 -6.163 -6.508 905.090 1611.434 0.379 100 1 
8q 428.541 3.832 1 7.50 0 -5.841 -6.251 916.992 1880.843 0.268 100 1 
8r 423.507 3.321 1 8.50 0 -5.422 -6.534 728.176 796.853 0.110 100 0 
8s 452.545 3.924 1 8.25 0 -5.958 -6.457 926.505 1004.805 0.318 100 1 
8t 456.964 4.383 1 7.50 0 -6.607 -6.534 905.090 2420.576 0.457 100 1 
8u 448.557 4.609 1 7.50 0 -6.596 -7.141 926.505 1102.894 0.523 100 1 
8v 478.583 4.643 1 8.25 0 -6.707 -6.975 916.992 1089.749 0.502 100 1 
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5.4. Experimental (in silico) 
5.4.1. Molecular docking simulation  
Molecular docking experiments were performed using Glide software package [4] 
implemented in Schrodinger Suite (2017_2) (Schrödinger, Inc., USA) unning on Intel CORE 
i7 based hpZ230 workstation with the Microsoft Windows 10 OS. The X-ray crystal structure 
of the protein was kept rigid, while the ligands were flexible throughout the simulation. 
5.4.2. Protein preparation 
The X-ray determined crystal structure of KSP complexed with a thiophene-containing 
inhibitor K-03 was retrieved from the PDB bearing ID 2UYM [3]. The protein was prepared 
using automatic preparation in the ‘Protein Preparation Wizard’ of Glide via the Optimized 
Potentials for Liquid Simulations 3 (OPLS3) forcefield. During the pre-processing stage, 
crystallographic water molecules, ADP (cofactor), and magnesium (metal ion) were removed 
and missing hydrogens were added to the protein structure. The tool neutralized the side 
chains that were far from the binding cavity and did not participate in the formation of salt 
bridges. The pre-processed protein structure was refined initially by optimizing the sample-
water orientation followed by a restrained minimization of the co-crystallized complex using 
OPLS3, which reoriented the side chain hydroxyl groups and alleviated potential steric 
clashes. Thus, the complex obtained was minimized until it reached the convergent of a 
heavy atom RMSD to 0.3 Å and finally taken in a .mae format. 
5.4.3. Grid file generation 
Receptor-grid generation protocol of Maestro 11.2 was used to define the binding site of the 
protein (2UYM) for the docking simulation by excluding any co-crystallized metals, co-
factors, and water molecules that may have crystallized during an experimental crystallization 
of KSP protein. A grid box was generated around the centroid of the cognate ligand (K-03) 
specifying the size (20 Å) for the docking with default settings and the output files were 
saved as a grid folder in .zip format. 
5.4.4. Ligand preparation 
Structures of the synthesized ligands and K-03 were sketched using 2D built panel of Maestro 
and taken in .mae format. LigPrep is a utility of Schrodinger software suit that combines tools 
for generating 3D structures from 1D (Smiles) and 2D (SDF) representation, searching for 
tautomers, steric isomers and perform a geometry minimization of the ligands. By employing 
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Ligprep protocol, all the ligands were prepared using OPLS3 with default settings and the 
output file were automatically saved in .maegz format. 
5.4.5. Docking simulation 
For the precision and accuracy of the docking protocols, the co-crystallized ligand (K-03) 
was extracted from the PDB structure (PDB ID: 2UYM) and docked using the Glide-docking 
algorithm (Schrodinger Inc.) in its extra precision (XP) mode without employing any specific 
constraints. A good correlation between the docked pose of K-08 and the cognate ligand in 
PDB structure was achieved in terms of binding orientation and molecular interactions with 
crucial amino acid residues of KSP that validated the default docking protocol for the 
subsequent docking of the synthesized ligands (8a-v). Hence, by specifying the ligands 
against the receptor grid, molecular docking was performed under Glide XP mode. 
5.4.6. Binding mode analysis  
The generated pose viewer files were imported to the Maestro interface and then all the 
protein-ligand complexes were investigated for various types of intermolecular (H-bond, 
halogen bond, salt bridges, π-π stacking, and π-cation) interactions and binding orientation, 
respectively by employing the XP visualizer module of Schrodinger software. 
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6.1. Summary and conclusion 
Cancer is one of the dreaded diseases in mankind accounting more than 8.8 million deaths in 
2015. Approximately, 70% of deaths from cancer occur in low- and middle-income countries. 
It is predicted that there will be 23 million new cancer cases by 2030 worldwide. Breast 
cancer is the second most common cancer among South African women population 
accounting 1 in every 26 women. Thus, social and economic burdens associated with cancers 
are severe at national and international levels. Hence, there is an urgent need for the 
development of more effective cancer therapeutics at this point of time. To accomplish this 
aspect, novel TDT hybrids were designed and synthesized as dual inhibitors of CDK and 
KSP, respectively for the cancer chemotherapy.  
1,3,4-Thiadiazole analogs are reported for versatile applications in the field of 
pharmaceuticals, medicinal chemistry, agricultural and material chemistry. They are also 
reported as anticancer agents acting through the profound inhibition of different kinases (KSP 
and ALK5). Similarly, thiazolone is one of the pharmaceutically important scaffolds known 
for their diverse medicinal properties for example, they are potent inhibitors of CDK. Hence, 
the aim of this study was to hybridize these potential anticancer scaffolds in one molecular 
platform to obtain potent anticancer compounds with dual mode of action conferring 
minimal/no side effects. 
Twenty-two novel TDT hybrid compounds (8a-v) were synthesized using multistep 
organic synthesis and well characterized by TLC, FT-IR, 1H NMR, 13C NMR, and HR-MS. 
All the title compounds (8a-v) were screened for their potential in vitro inhibition against the 
validated anticancer drug targets (CDK, Abl and KSP). Results obtained from these 
evaluations suggested that the synthesized compounds are indeed potent inhibitors of CDK 
and KSP confirming dual mode of action.  
In chapter 2, we have performed comprehensive literature survey and presented a 
glimpse on different aspects such as cancer, statistics, therapy, chemotherapeutic agents, 
kinase targets, CDKs, KSP and molecular modelling studies. The inspiring literature reports 
encouraged us to design novel TDT hybrids as potential chemotherapeutic agents. In the 
chapter 3, we have described the synthetic strategy adopted for the synthesis of novel hybrids 
(8a-v). The designed scheme was very facile which resulted the desired compounds 8a-v with 
good yields (70-89%). The title compounds (8a-v) were obtained by treating different 
aldehydes (7a-v) with an intermediate compound 6 (1,3,4-thiadiazol-2-yl)amino)thiazol-
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4(5H)-one) via a Knoevenagel condensation reaction. Structures of all the synthesized 
compounds were characterized using the IR, 1H NMR, 13C NMR, and HR-MS spectra.  
Chapter 4 describes the in vitro kinase inhibition and cytotoxicity evaluation of the 
synthesized compounds 8a-v. The synthesized derivatives were screened for their potential 
inhibition of two kinase targets (CDK2/ cyclin E, Abl kinase) together with cytotoxicity 
evaluation against K-562 and MCF-7 cell lines. From the in vitro kinase inhibition data, one 
of the final compounds 8h was identified as lead compound with IC50 value of 3.1 µM 
against CDK2 enzyme. The promising cytotoxicity (GI50 = 6.25 µM) evaluation of the 
compounds further supported the anticancer potential of the lead compound 8h. From the 
SAR analysis (CDK-2), an electron-withdrawing halogen (Cl) at the ortho position of the 
aromatic ring (8h) demonstrated higher potency (IC50 = 3.1 µM) followed by the substitutions 
at para- and meta position displaying IC50 of 3.4 µM and 3.9 µM for 8t and 8o, respectively. 
Surprisingly, a couple of compounds (8j and 8k) exhibited higher inhibition (IC50 >12.5 µM) 
against the Abl kinase when compared with the standard roscovitine (IC50 >100 µM). In 
comparison to the standard drugs (roscovitine and imatinib), the inhibitory profiles of all the 
final compounds 8a-v against MCF-7 were good indicating that 8a-v can be considered as 
potential anti-breast cancer hit compounds. Molecular docking studies against the CDK2 
protein (PDB ID: 2A4L) revealed crucial molecular interactions required for in vitro 
inhibition of the synthesized compounds supporting our SAR analysis.  
In the chapter 4, we discussed the in vitro evaluation 8a-v against the steady state 
basal- and MT-stimulated KSP ATPase activities. The in vitro screening results presented no 
characteristic inhibition of state basal KSP ATPase, while good inhibition was observed 
against MT-stimulated KSP ATPase activity. From the evaluated derivatives, 8h displayed 
the highest inhibition with an IC50 value of 13.2 µM against the MT-stimulated KSP ATPase 
activity. Similarly, compounds 8f and 8i also showed promising inhibition with IC50 of 17.2 
µM and 20.2 µM, respectively. A brief SAR analysis (KSP), indicated that 2-chloro and 4-
nitro substituents on the phenyl ring of the thiazolone motif contributed significantly to the 
enzyme inhibition. An in silico molecular docking study using the crystal structure of KSP 
(PDB ID: 2UYM) further supported the SAR and extrapolated the importance of crucial 
molecular ligand-protein interactions in influencing the in vitro enzyme inhibition. The 
magnitude of the electron-withdrawing functionalities over the hybrids and the critical 
molecular interactions with the enzyme imparted the compounds toward higher in vitro 
potency. The drug-like properties of the synthesized final compounds 8a-v were also 
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calculated based on the Lipinski's rule of five and in silico computation of key 
pharmacokinetic parameters (ADME).  
Thus, the research work finally concluded that the hybrid molecules (8a-v) are novel 
and potential dual inhibitors of CDK2 and KSP with promising drug-like properties for future 
development as anti-breast cancer agents. 
6.2.  Future studies 
As most of the synthesized compounds exhibited promising anticancer activity through the 
inhibition of potential drug targets (CDK2 and KSP), the generated in vitro results can be 
effectively used as a preliminary data for further lead optimization using three-dimensional 
quantitative structure activity relationship (3D-QSAR) models. Using the 3D-QSAR models, 
the IC50 values of the compounds that are not synthesized will be predicted and can be further 
optimized structurally to improve the pharmaceutical properties (solubility, cell permeability 
and efficiency) through the development of 3D Quantitative Structure-Property Relationship 
(3D-QSPR) models. Thus, potential lead compounds identified by above mentioned 
computer-aided design techniques will be synthesized and evaluated by in vitro enzyme 
inhibition (CDK2 and KSP). Moreover, in depth mechanistic studies will be conducted to 
deduce mode of action of compounds with biological systems. From the in vitro cytotoxicity 
results of the compounds against K-562 and MCF-7 cell lines, it was observed that all the 
synthesized final compounds can be further developed as anti-breast cancer compounds. To 
accomplish this task, ligand (3D-QSAR and pharmacophore modeling) and structure-based 
drug design techniques (molecular docking and molecular dynamics) will be employed 
integrating molecular hybridization/ bioisosteric replacement strategies. Thus, the research 
work will be extended potentially through a combination of effective computer-aided drug 
design tools and modern synthetic medicinal chemistry approaches to develop novel 












7.1. Spectral images  
 
Figure S1: 1H NMR of compound 2 
 




Figure S3: 1H NMR of compound 3 
 





























Figure S11: 1H NMR of compound 8a 
 
 












Figure S15: 1H NMR of compound 8b 
 
 




Figure S17: HR-MS of compound 8b 
 
 






























Figure S25: HR-MS of compound 8d 
 
 




Figure S27: 1H NMR of compound 8e 
 
 




Figure S29: HR-MS of compound 8e 
 
 




Figure S31: 1H NMR of compound 8f 
 
 














Figure S35: 1H NMR of compound 8g 
 




Figure S37: FT-IR of compound 8h 
 
 












Figure S41: FT-IR of compound 8i 
 
 





Figure S43: 13C NMR of compound 8i 
 
 




Figure S45: 1H NMR of compound 8j 
 
 


















































Figure S57: FT-IR of compound 8n 
 
 














Figure S61: 1H NMR of compound 8o 
 
 





Figure S63: FT-IR of compound 8p 
 
 













Figure S67: FT-IR of compound 8q 
 
 





Figure S69: 13C NMR of compound 8q 
 
 






Figure S71: FT-IR of compound 8r 
 
 














Figure S75: FT-IR of compound 8s 
 
 













Figure S79: 1H NMR of compound 8t 
 
 






Figure S81: FT-IR of compound 8u 
 
 













Figure S85: FT-IR of compound 8v 
 
 





Figure S87: 13C NMR of compound 8v 
 
 






7.2. Inhibition of MT-stimulated KSP ATPase activity profiles 
 
Figure S89: Inhibition of MT-stimulated KSP ATPase activity by 8a 
 
 




Figure S91: Inhibition of MT-stimulated KSP ATPase activity by 8c 
 
 





Figure S93: Inhibition of MT-stimulated KSP ATPase activity by 8e 
 
 




Figure S95: Inhibition of MT-stimulated KSP ATPase activity by 8g 
 
 




Figure S97: Inhibition of MT-stimulated KSP ATPase activity by 8i 
 
 




Figure S99: Inhibition of MT-stimulated KSP ATPase activity by 8k 
 
 




Figure S101: Inhibition of MT-stimulated KSP ATPase activity by 8m 
 
 




Figure S103: Inhibition of MT-stimulated KSP ATPase activity by 8o 
 
 





Figure S105: Inhibition of MT-stimulated KSP ATPase activity by K858 
